Frequently Asked Questions

Red blood cells

Kidney disease

Yes, vitamin B12 is naturally present in foods of animal origin, including fish, meat, poultry, eggs, and dairy products. In addition, fortified breakfast cereals and fortified nutritional yeasts are readily available sources of vitamin B12 that have high bioavailability. The bioavailability of vitamin B12 is about three times higher in dairy products than in meat, fish, and poultry, and the bioavailability of vitamin B12 from dietary supplements is about 50% higher than that from food sources. Vegans are at increased risk for developing vitamin B12 deficiency. From NIH.

*DV = Daily Value. The U.S. Food and Drug Administration (FDA) developed DVs to help consumers compare the nutrient contents of foods and dietary supplements within the context of a total diet. The DV for vitamin B12 is 2.4 mcg for adults and children aged 4 years and older [21]. FDA does not require food labels to list vitamin B12 content unless vitamin B12 has been added to the food. Foods providing 20% or more of the DV are considered to be high sources of a nutrient, but foods providing lower percentages of the DV also contribute to a healthful diet. From NIH

Yes. In some centers, the DAT (direct antiglobulin test) has largely replaced the term Coombs test. Coombs test was named after Robin Coombs, a British immunologist who developed the principle behind the antiglobulin test while travelling back to Cambridge on a wartime train.

Yes

Yes. Learn more here.

Fragmented RBCs can be detected by certain automated hematology analyzers based on analysis of fraction of small red blood cells (RBCs) in the context of normal RBC volume indices (mean corpuscular volume and width). Their presences should prompt a peripheral blood smear review.

Figure: A specific area below the RBC area in the RET scattergram is used for identification of fragmented red blood cells. Due to the absence of nucleic acids in red blood cells the intensity of the measured side fluorescence signals (SFL) is extremely low. In addition, the high-angle forward scatter (FSC) is lower than that of intact red blood cells. Each cell is plotted in the RET scattergram based on its fluorescence intensity (SFL on x-axis) and its high-angle forward scatter (FSC on y-axis), which reflects characteristics of both cell size and cellular content. The triangle indicates the detection area for fragmented red blood cells (FRC). Source.

Rarely, haptoglobin (Hp) levels are normal or increased in hemolysis owing to inhibition of the macrophage uptake of the haptoglobin-hemoglobin complex (Hp-Hb) by the CD163 receptor.

Hb, hemoglobin; Hp, haptoglobin; liver, upper left; lysed red cell, upper right; macrophage, bottom.

Yes! AABB states that a single unit RBC transfusion should be standard in nonbleeding, hospitalized patients and additional units prescribed only after reassessment of patient and hemoglobin (Hb) level.

Food and Drug Administration (FDA) regulations permit hemochromatosis patients to donate blood, provided the donor (the hemochromatosis subject) meets standard blood donor eligibility criteria.

The American Red Cross does not permit hemochromatosis patients to donate blood because it “has a long-standing policy that potential donors are not allowed to receive direct compensation for their donation (beyond the usual orange juice and cookie). Because people with hemochromatosis would otherwise have to pay for their therapeutic phlebotomies, they would in effect be getting something of value for being able to donate for free. Thus the Red Cross has ruled that such donations violate their policy” (read more here).

Bottom line: blood-collection organizations can determine their own protocols within U.S. Food and Drug Administration regulations, which stipulate acceptable iron levels in donated blood.

In a 2016 Editorial, West and Eder wrote:

Safety concerns historically stem from the possibility of creating an incentive to donate blood for free rather than to pay for therapeutic phlebotomy, possibly encouraging HH donors to deny risk factors for infectious diseases. In the Final Rule that became effective in May 2016, the US Food and Drug Administration codified the requirements for hereditary hemochromatosis (HH) donors in the Code of Federal Regulations (CFR), thus eliminating the need for a variance to collect whole blood more frequently than every 8 weeks (or double red blood cells more frequently than every 16 weeks) and distribute units without special labeling from HH donors who meet all eligibility requirements. Notably, the CFR retains the requirement for obtaining a prescription for therapeutic phlebotomy from a licensed health care provider and performing therapeutic phlebotomy free of charge… Since the molecular basis of the disease was elucidated in 1996, it has been posited that the condition itself poses no harm to the recipient. The question concerns the motives of the HH donor to give blood and the possibility of incentive to withhold information from blood establishments about infectious risk factors

CFR – Code of Federal Regulations Title 21 from the FDA, current as of March 29 2022.
Exceptions and Alternative Procedures Approved Under 21 CFR 640.120 in 2018, from the FDA.

In 2016, the American Red Cross wrote (despite its continued refusal to allow patients with HH to donate blood) a piece titled “Iron-rich blood is just fine, thank you!”:

For decades, blood centers in the United States would not collect whole blood from donors/patients with hereditary hemochromatosis (HH), in some cases because it used to be that such units had to be labeled with the disease necessitating its removal… In 2016, the FDA encoded the regulations for therapeutic phlebotomy… Special labeling is not required, and units may be distributed if they meet regular requirements and criteria, as long as the therapeutic phlebotomy (TP) is ordered by a physician and the phlebotomy performed without charge.

Rarely, owing to skewed X chromosome inactivation. Learn more here.

Yes, G6PD seems to be protective, as are many of the hemoglobinopathies and ethnic neutropenia. Learn more about hemoglobinopathies and malarial infection here.

SE, South East; HS, hereditary stomatocytosis

Represents number of nucleated red blood cells (nRBCs) in peripheral blood.

Typically enumerated by one of the following:

  • Manual counting of Wright-Giemsa-stained peripheral smears as art of the traditional 100-cell manual differential leukocyte count – reported as number of nRBCs per 100 white blood cells (WBCs).
  • Automated hematology analyzers (for example, Sysmex) – reported as relative number of nRBCs per 100 WBCs or as an absolute number.
From Sysmex
In the WNR Channel, the analyzer measures side fluorescence and forward scatter. Side fluorescence measures the nucleic acid content to identify NRBCs in the same channel in which white cells are counted. Forward scatter measures cell size. WNR, white count and nucleated red blood cells. Source.

1) Reticulocyte stain:

The traditional method of measuring the reticulocyte count is a manual method that uses supravital stains (such as methylene blue) to highlight the reticulum (RNA) network of this immature red cell fraction. A lab technologist uses a microscope to count the number of such cells relative to the number of mature red blood cells. The number of reticulocytes is reported as a percentage of total red blood cells.

2) Automated analyzer:

The number of reticulocytes can be measured directly by most automated analyzers by staining the remnant RNA with a fluorescent dye. The number of reticulocytes is reported as an absolute count.

Scattergram of the RET channel with a normal cell distribution. In the RET channel, the lysis reagent slightly perforates the cell membranes of red blood cells, white blood cells and platelets and so allows the fluorescence marker to penetrate the cell. The fluorescence marker labels the intracellular nucleic acids whereby the intensity of the resulting fluorescence signal is directly proportional to the nucleic acid content. Using the forward scattered light and the fluorescence signal, the reticulocytes can be separated from mature red blood cells. Source.

About one-half of patients with sickle cell disease have chronic ophthalmologic complications.

30%-70% of patients, including nausea, vomiting, diarrhea, constipation, epigastric pain, and metallic taste.

Prevalence is 25-30%.

Prevalence is 10%-40% in adults with sickle cell disease (less common in children).

Thrombocytosis occurs in about 10-15% of patients with iron deficiency anemia. Learn more here.

If Hct > 54%, either reduce or stop testosterone therapy or initiate phlebotomy while continuing testosterone therapy.

Let’s look at the clinical practice guidelines:

2017 British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, With Statements for UK Practice:

J Sex Med. 2017;14:1504-1523.

2018 Evaluation and Management of Testosterone Deficiency: AUA Guideline:

J Urol. 2018;200:423-432.

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline:

Erythrocytosis = hematocrit > 54%.

Glucose indirectly represses ALA synthase.

Hemin (available in the United States as Panhematin) suppresses aminolevulinic acid (ALA) synthase activity and thereby decreases overproduction of ALA and porphobilinogen (PBG).

Leukocyte reduction filters are used to remove > 99.9% of leukocytes. According to the AABB, leukocyte-reduced units of red blood cells must have a residual content of leukocytes <5.0 x 106.

About 70% of patients with pernicious anemia have macrocytosis. Learn more here.

Small clinically silent PNH clones are found in up to 70% of adults. Learn more here.

In the US:

  • For men – ≥ 13 g/dL (130 g/L) or Hct level ≥ 39%
  • For women – ≥ 12.5 g/dL (125 g/L) or Hct level ≥ 38%

Reduction in hemoglobin ≥ 2 g/dL (20 g/L) below baseline (per NIH 2014 clinical practice guideline).

Two main classification schemes: 1) based on kinetics (hypoproliferative vs. hyperproliferative); 2) based on red cell morphology (microcytic [with or without hypochromia]) vs. normocytic vs. macrocytic). Image of morphological classification here.

Elevated urine porphobilinogen (PBG) confirms diagnosis in acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), or variegate porphyria (VP). PBG level is normal in the very rare ALA dehydratase deficiency porphyria. Discriminating between AIP, HCP, and VP requires additional testing.

Absolute erythrocytosis (elevated red blood cell mass) and apparent or relative erythrocytosis (reduced plasma volume relative to red blood cell mass). Absolute erythrocytosis is further divided into primary or secondary depending on whether the cause is intrinsic or extrinsic to the red blood cell.

P. vera, polycythemia vera; ODC, oxygen dissociation curve; R-L shunt, right to left shunt; EPO, erythropoietin.

Learn more here.

Urine dipstick positive for blood, urine microscopy negative for red cells.

  • Presence of elliptocytes on peripheral blood smear (fragmented red blood cells may also be seen).
  • Associated with increased osmotic fragility.
  • Osmotic gradient ektacytometry shows characteristic deformability profiles with curve exhibiting a trapezoidal form with a decrease in the RBC deformability.
  • DNA testing panels can define the pathogenic mutations in alpha-spectrin, beta-spectrin, and protein 4.1 in HE.

International Council for Standardization in Haematology (ICSH) guidelines one laboratory diagnosis of nonimmune hereditary red cell membrane disorders:

Osmotic deformability profiles of red cells from normal control and HE. HE is characterized by a trapezoidal curve with moderately decreased IDmax but normal Omin and Ohyper results.

Learn more here.

  • Presence of spherocytes on peripheral blood smear
  • Increased mean corpuscular hemoglobin concentration (MCHC) (> 36 g/dL [360 g/L])
  • Increased lysis in osmotic fragility test and reduced fluorescence signal in eosin-5-maleimide (EMA) binding test

Diagnosis of HS does not necessarily require molecular analysis of affected genes.

2012 British Committee Standards in Haematology (BCSH) expert guideline on diagnosis of hereditary spherocytosis recommendations:

Flow cytometry using ≥ 2 different monoclonal antibodies against 2 different glycosylphosphatidylinositol (GPI)-anchored proteins (GPI-APs) on ≥ 2 different blood cell lineages. Learn more here.

  • Mild HS
    • Normal Hb level with reticulocytes < 6%.
    • May require 0-1 transfusion during lifetime and rarely splenectomy.
  • Moderate HS
    • Hb level > 8 g/dL (80 g/L) with reticulocytes 6%-10%.
    • May require 0-2 transfusions during infancy and in some cases splenectomy (if the capacity level is decreased).
  • Moderately severe HS
    • Hb level 6-8 g/dL (60-80 g/L) with reticulocytes > 10%.
    • May require > 2 transfusions intermittently and splenectomy likely necessary.
  • Severe HS
    • Hb level 10%.
    • Require regular transfusions and splenectomy likely necessary.

2012 British Committee Standards in Haematology (BCSH) expert guideline on diagnosis of hereditary spherocytosis:

Learn more here.

By dividing the hematocrit (Hct) by the red blood cell count (RBC).

MCV = Hct/RBC

For example:
45% = 5 x 1012/L x 90 x 10-15L
0.45=450×10-3

Analysis by automated hematology analyzer should be performed ideally within 6 hours of collection in EDTA-coated tubes.

  • 21 days if stored in citrate phosphate dextrose (CPD), or CPD2 anticoagulant-preservative
  • 35 days if stored in citrate phosphate dextrose adenine 1 (CPDA-1)
  • 42 days using current generation of additive solutions additive solutions

Continue oral iron for 3-6 months after the iron deficiency has been corrected in order to replenish iron stores.

About 4,500

Ferritin Structure: Apoferritin forms a roughly spherical container within which ferric iron is stored as a ferrihydrite mineral. Apoferritin refers to the iron-free form of the protein; the iron-containing form is termed holoferritin or simply ferritin. The apoferritin shell is composed of 24 subunits of two types, termed H and L, the ratio of which varies widely depending on tissue type and inflammation. Iron is toxic in cellular systems because of its capacity to generate reactive species (shown as yellow spheres) which can directly damage DNA and proteins. From Knovich et al.
ferritin structure
Ferritin is a hollow protein shell composed of 24 subunits. Two subunits have been removed to allow visualization within the core where up to 4500 iron atoms can be stored. Source

100 million per year worldwide, 13 million in the US.

About 2 x 1011 (200 billion) or 1% of all red cells

About 200 × 109 per day

There are 8 enzymes in the heme biosynthesis pathway. Mutations in each enzyme can cause porphyria. Therefore there are 8 different kinds of porphyria.

Heme biosynthesis pathway

1-2 mg is derived from intestinal absorption.

Regulation of systemic iron metabolism. Organs and cell types involved in systemic iron
balance are shown. Duodenal enterocytes absorb dietary iron via DMT1 located on the
apical surface upon reduction of Fe3+ to Fe2+ by DcytB. Splenic reticuloendothelial
macrophages recycle iron from senescent red blood cells. Both cell types release iron via
ferroportin with the aid of hephaestin, which oxidizes Fe2+ to Fe3+. Iron is also oxidized by
ceruloplasmin in the circulation. Plasma Tf captures and circulates iron in the body. Hepatic
hormone, hepcidin regulates iron efflux from these cells by regulating the stability of
ferroportin. Synthesis and secretion of hepcidin by hepatocytes is influenced by iron levels
in the body as well as conditions that affect iron metabolism indirectly such as
inflammation, ER stress, erythropoiesis, and hypoxia. From Pantopoulos et al.

Each unit of RBCs (processed from 420 mL of donor blood) contains about 200 mg of iron (0.47 mg iron/mL of whole donor blood or 1.08 mg iron/mL of pure RBCs).

The human body normally contains 40 to 50 mg/kg of iron, which amounts to 3-4 grams. It is distributed in the following compartments:

  • Hemoglobin in RBCs – about 30 mg/kg
  • Myoglobin in muscle – about 4 mg/kg
  • Iron-containing enzymes – about 2 mg/kg
  • Storage in ferritin and hemosiderin – 0-2,000 mg
  • Plasma transferrin – 1-2 mg

About 25 mg of iron daily (far more than the 1 mg that is absorbed by the gastrointestinal track).

25-40% larger; mean cell volume about 120 fL, though quite variable. Learn more here.

About 10%-20% of cases remain unexplained.

Hemoglobin typically increases by 20 g/L at 2 weeks, with a normal hemoglobin level usually achieved in 2 months. Ferritin may take up to 6 months to return to normal.

No

IV carbohydrate loading has potential risk of hyponatremia, which can lead to cerebral edema.

According to the British Society of Haematology:

  • Hct > 52% in men persisting for > 2 months
  • Hct > 48% in women persisting for > 2 months

No, it must be ordered separately.

Yes, and this is the justification for periodic surveillance endoscopies in these patients. Learn more here.

Yes. Cyanocobalamin is a synthetic form of vitamin B12 found only in supplements.

Yes, typically for complement only. However, it is also weakly positive for IgG in about one quarter of cases. Learn more here.

X-linked. Learn more here.

No, about 30% of cases occur in patients without anemia. This is called isolated macrocytosis.

No, it is also seen in children and during pregnancy (more common at the beginning of pregnancy than in late pregnancy).

Yes, on both venous and arterial sides of the circulation. Learn more here.

Serum erythropoietin is low in about 90% of patients with polycythemia vera. Learn more here.

Retinopathy has been reported in 70% of patients with HbSC compared with about 45% in sickle cell anemia. Learn more here.

No. It is also seen in:

  • Pregnancy
  • Chronic kidney failure
  • Major depressive disorder
  • Generalized anxiety disorder
  • Panic disorder
  • Attention-deficit/hyperactivity disorder

No. Serum iron levels are highly dependent on recent food intake and they follow a diurnal rhythm (though there is no evidence that fasting samples perform better than random samples). Learn more here.

1-5 mg/day

According to DailyMed: Daily doses greater than 1mg do not enhance the hematologic effect, and most of the excess is excreted unchanged in the urine. The usual therapeutic dosage in adults and children (regardless of age) is up to 1mg daily. Resistant cases may require larger doses.

Guidance varies by professional organization.

AGA clinical practice guidelines on the gastrointestinal evaluation of iron deficiency anemia:

British Society of Gastroenterology (BSG) guideline on management of iron deficiency:

Hemoglobin (Hb) and hematocrit (Hct). Hct correlates a little better with red cell mass compared with Hb (learn more here).

Depends on the clinical context. In patients with anemia, we should refer to Hb because oxygen carrying capacity is limiting, whereas the Hct should be considered in those with polycythemia since blood viscosity is limiting. For those with normal Hb/Hct, both oxygen carrying capacity and blood viscosity are at equipoise, so take your choice!

2020 AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia:

The RDW-CV (RDW coefficient of variation) is inversely proportional to the mean cell volume (MCV). As a result, patients with microcytosis have elevated RDW-CV regardless of variation in cell size, while those with macrocytosis have lower RDW-CD values. By contrast, the RDW-SD (RDW standard deviation) is not influenced by the MCV and therefore may be preferable to use. An RDW-SD > 46 fL represents anisocytosis.

Hydroxyurea (since 1998), L-glutamine, crizanlizumab, voxelotor

  • Acute hemolytic transfusion reaction (AHTR)
  • Febrile nonhemolytic transfusion reactions (FNHTR)
  • Urticaria
  • Anaphylaxis
  • Transfusion-related acute lung injury (TRALI)
  • Transfusion-associated circulatory overload (TACO)
  • Nonimmune hemolysis
  • Hypotensive transfusion reactions
  • Transfusion-associated sepsis

Blood loss, hemolysis, erythropoietin administration, high altitude

  • Changes in hemoglobin oxygen affinity, for example high-affinity hemoglobin mutations.
  • Mutations in oxygen sensing/hypoxia-inducible factor (HIF) signaling pathway, for example Chuvash polycythemia (mutation in VHL gene, automosomal recessive).
Under normal oxygen conditions, PHD proteins (PHD1, PHD2, and PHD3) have an hydroxylate HIF-α at the oxygen-dependent domain of HIF-α. Following this, VHL associates with HIF-α, providing a recognition site for the ubiquitin ligase complex. The HIF-α is then degraded by ubiquitination in the proteasome. In hypoxic conditions, prolyl hydroxylation does not occur and PHD cannot associate with VHL and ultimately go down the pathway of ubiquitination. Instead, HIF-α accumulates and associates with HIF-β. HIF-α and HIF-β form a stable HIF complex which translocates to the nucleus and binds to promoters and enhancers of a range of genes. This leads to transcription of a number of genes, including erythropoietin. Mutation in the genes in the oxygen sensing pathway could lead to abnormal protein production, which would not undergo ubiquitination in states of normal oxygen tension but instead behave as if in a state of hypoxia. In addition, mutations in Hb that cause a left shift of the Hb–oxygen dissociation curve (high affinity for oxygen) causes reduced oxygen release to the tissues. The result is tissue hypoxia, EPO production and erythrocytosis. Gain of function mutations in erythropoietin and the erythropoietin receptor may also result in erythrocytosis. EPO, erythropoietin; EPOR, erythropoietin receptor; PHD, prolyl hydroxlase; VHL, von Hippel Lindau; HIF, hypoxia inducible factor.

Learn more here

Primary

  • Congenital (erythropoietin receptor mutations)
  • Polycythemia vera
  • Idiopathic erythrocytosis

Secondary

  • Congenital
    • Defects in oxygen sensing pathway – Chuvash erythrocytosis (VHL mutation)
    • Left shift of hemoglobin (Hb) oxygen dissociation curve:
      • High affinity Hb
      • 2,3-DPG deficiency
  • Acquired
    • Hypoxia-driven:
      • Central process:
        • Chronic lung disease
        • Right-to-left cardiopulmonary shunts
        • Carbon monoxide poisoning
        • Smoking
        • Sleep apnea
        • High altitude
      • Local process:
        • Renal artery stenosis
        • Hydronephrosis
        • Renal cysts
    • Pathological erythropoietin production:
      • Tumors:
        • Hepatocellular carcinoma
        • Renal cell cancer
        • Cerebellar hemangioblastoma
        • Uterine leiomyoma
        • Pheochromocytoma
        • Meningioma
    • Drug-associated:
      • Erythropoietin
      • Androgens
      • Diuretics
Epo, erythropoietin; ODC, oxygen dissociation curve; R-L shunts, right-to-left shunts; CO, carbon monoxide; P. vera, polycythemia vera.

Learn more here.

Broad overview of anemia, showing causes of hemolytic anemia. TMA, thrombotic microangiopathy; MAHA, macroangiopathic hemolytic anemia; SCD, sickle cell disease; HS, hereditary spherocytosis; HE, hereditary elliptocytosis; PNH, paroxysmal nocturnal hemoglobinuria; PKD, pyruvate kinase deficiency.
First branchpoint in diagnostic algorithm is immune vs. non-immune hemolysis. Virtually all cases of immune-mediated hemolysis (whether alloimmune or autoimmune) will be associated with a positive direct antiglobulin test (DAT) (Coombs test).
If the DAT is negative, the differential diagnosis includes extracorpuscular and intracorpuscular non-immune conditions. Extracorpuscular causes are those in which the red cells are innocent bystanders, reacting to changes in their extracellular environment. Intracorpuscular causes are those that are inherent in the red cell itself.
Intracorpuscular causes of hemolysis involve three broad categories: defects in hemoglobin, membrane or enzymes. The hemoglobin ‘bucket’ includes thalassemia and sickle cell disease; membrane causes include hereditary spherocytosis, hereditary elliptocytosis and hereditary stomatocytosis, and paroxysmal nocturnal hemoglobinuria (PNH; the only acquired condition in the intracorpuscular category); and defects in enzymes causing hemolysis include G6PD and pyruvate kinase deficiencies.
On the extracorpuscular side are conditions associated with thrombotic microangiopathy, including primary and secondary thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS), and disseminated intravascular coagulation (DIC); and a series of non-TMA causes (“other”) including burns/thermal injury, microangiopathic hemolytic anemia from prosthetic valves or foot strike anemia, Clostridial sepsis, Wilson’s disease and spur cell anemia.

Nucleated red blood cells are a reflection of extreme increases in erythropoietic activity as seen in/with:

  • Hemoglobinopathies
  • Brisk hemolysis
  • Rapid blood loss
  • Other conditions of hematopoietic stress such as sepsis
  • Damage or stress to bone marrow, for example in:
    • Chronic myeloid leukemia
    • Acute leukemia
    • Myelodysplastic syndromes
  • Chemotherapy
  • Myelophthisic conditions, including:
    • Metastatic cancer to bone marrow
    • Bone marrow fibrosis
GI, gastrointestinal, GU, genitourinary; IV, intravascular.

Lactate dehydrogenase (LDH), indirect (unconjugated) bilirubin, haptoglobin, and AST. Learn more here.

Hemolysis associated with elevated serum levels of leakage products, LDH and AST; reduced levels of haptoglobin (Hp) owing to binding to free Hb and internalization in macrophages (without recycling); and elevation of unconjugated (indirect) bilirubin from breakdown of heme inside macrophages.
  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Epigastric pain
  • Metallic taste

Large precipitates of denatured hemoglobin); often seen in patients with G6PD deficiency and hemolysis. Requires special stain of blood using methyl violet. See images.

  • Those at risk for transfusion-associated graft-versus-host disease (TA-GVHD) caused by proliferation of donor T lymphocytes
  • Those who are immunocompromised
  • Those receiving intrauterine transfusion
  • Those with hematologic malignancies or solid tumors, including:
    • Sarcoma
    • Neuroblastoma
    • Hodgkin lymphoma
  • Those who are recipients of marrow or peripheral blood stem cell transplantation
  • Those receiving RBCs from blood relatives or human leukocyte antigen-compatible donors
  • Those receiving fludarabine therapy
  • Those receiving granulocyte transfusions

According to the AABB:

Description:

  • Blood components that contain viable lymphocytes may be irradiated to prevent proliferation of T lymphocytes, which is the immediate cause of TA-GVHD.
  • Irradiated blood is prepared by exposing the component to a radiation source.
  • The standard dose of gamma or X-ray irradiation is 2500 centigray (cGy) targeted to the central portion of the container with a minimum dose of 1500 cGy delivered to any part of the component.

Indications:

  • Patients at risk for TAGVHD, including:
    • Fetal and neonatal recipients of intrauterine transfusions
    • Selected immunocompromised recipients
    • Recipients of cellular components known to be from a blood relative
    • Recipients who have undergone peripheral blood progenitor cell transplantation
    • Recipients of cellular components whose donor is selected for HLA compatibility and recipients of granulocyte transfusions.
    • Patients receiving purine analogues (eg, fludarabine, cladribine) or certain other biological immunomodulators (eg, alemtuzumab, antithymocyte globulin) who may be at risk for TA-GVHD, depending on clinical factors and the source of the biological agent.
  • Symptomatic hemolytic anemia
  • Presence of gallstones
  • Large reduction in exercise tolerance
  • Growth retardation
  • Skeletal changes or leg ulcers due to HS
  • Extramedullary hematopoietic tumors
  • Vascular compromise of vital organs in older patients
  • Splenic infarct with pain or early satiety from splenomegaly

Consider delaying splenectomy until > 6 years old if possible.

Guideline recommendations:

Recommendations regarding splenectomy in hereditary hemolytic anemias by Splenectomy in Rare Anemias Study Group (2017):

2012 British Committee Standards in Haematology (BCSH) expert guideline on diagnosis of hereditary spherocytosis:

Patients should be selected for splenectomy on the basis of their clinical symptoms and presence of complications such as gallstones, not simply on the basis of the diagnosis alone (grade 2 recommendation, grade C evidence). Splenectomy should be performed in children with severe HS, considered in those who have moderate disease, and should probably not be performed in those with mild disease. A careful history is important in those with moderate to mild disease to establish if there is evidence suggesting reduced exercise tolerance; the metabolic burden of increased marrow turnover may be considerable. Where there is a family history, the benefit of splenectomy in other individuals may help determine whether to proceed.
  • Patients intolerant or not responding to oral iron.
  • When there is a need for a quick recovery in patients with iron deficiency anemia.
  • Patients taking erythropoiesis stimulating agent (ESA), for example those with anemia of chronic kidney disease.
  • Patients with inflammatory bowel disease inflammatory bowel disease and iron deficiency anemia.
  • Patients with history of severe allergic reactions to plasma-containing products.
  • Patients who have absolute immunoglobulin A (IgA) deficiency and for whom no IgA-deficient RBCs are available.
  • Patients at risk of hyperkalemia.
  • Neonates with neonatal alloimmune thrombocytopenia requiring maternal RBC transfusion that contains antihuman platelet antigen-1a (however, use of washed RBCs is not required.)

According to AABB:

  • Description:
    • Washed components are typically prepared using 0.9% Sodium Chloride, Injection USP with or without small amounts of dextrose.
    • Washing removes unwanted plasma proteins, including antibodies and glycerol from previously frozen units.
    • The shelf life of washed components is no more than 24 hours at 1 to 6 C or 4 hours at 20 to 24 C.
    • Washing is not a substitute for leukocyte reduction, and only cellular components should be washed.
  • Indications:
    • To reduce exposure to antibodies targeting known recipient antigens.
    • To remove constituents that predispose patients to significant or repeated transfusion reactions (eg, removal of IgA-containing plasma in providing transfusion support for an IgA-deficient recipient or in rare recipients experiencing anaphylactoid/anaphylactic reactions to other plasma components).


Less avascular necrosis, pulmonary hypertension, leg ulcers, and stroke; more retinopathy. 0.4% painful crises per patient year in those with HbSC, less than half the rate in sickle cell anemia. Learn more here.

ComplicationHbSCHbSS
Avascular necrosis++++
Pulmonary hypertension++++
Leg ulcers++++
Stroke++++
Retinopathy++++
Painful crises ++++

Conditions associated with:

  • Appropriate release of erythropoietin from oxygen sensing cells in the kidney, including:
    • Cardiopulmonary disease
    • High altitude
    • Hereditary hemoglobin mutations associated with high oxygen affinity
  • Inappropriate release of erythropoietin from:
    • Oxygen sensing cells in the kidney, including renal disorders and drugs
    • Tumor cells.
P. vera, polycythemia vera; ODC, oxygen dissociation curve; R-L shunt, right to left shunt; EPO, erythropoietin.

See list of causes from PMC7829024. Learn more here.

  • Increase in cardiac output, primarily from increased stroke volume
  • Increase in 2,3-diphosphoglycerate (2,3-DPG), leading to shift of oxygen dissociation curve to the right (lower affinity for oxygen, increased oxygen unloading in tissues)
  • Increase in oxygen extraction by tissues
  • Redistribution of blood flow to vital tissues such as the brain and heart

  • Renal artery stenosis
  • Hydronephrosis
  • Renal cysts
  • Renal tumors

  • Cerebellar hemangioblastoma
  • Hepatocellular carcinoma
  • Uterine leiomyoma
  • Renal cell carcinoma
  • Meningioma
  • Fatigue
  • Pallor
  • Dizziness
  • Headaches
  • Vertigo
  • Tinnitus
  • Dyspnea
  • Inactivity

Learn more here.

Teardrop cells are red cells appearing in the shape of a teardrop or a pear with a single, short or long, often blunted or rounded end are called teardrop cells. True tear drops have blunted tips and point in different directions. Teardrop cells are commonly seen in chronic idiopathic myelofibrosis.

Teardrop cell (arrow) from a 68-year-old woman with cirrhosis (100x, oil).

Hemoglobinuria and myoglobinuria

Type I cells – red blood cells (RBCs) express GPI-APs (for example, CD59) at normal density

  • RBCs express normal amounts of GPI-anchored proteins (GPI-AP), such as CD59
  • Full protection against complement-mediated lysis
  • Normal RBC lifespan of about 120 days

Type II cells – red cells partly deficient in GPI-APs;

  • RBCs partly deficient in GPI-APs
  • Partial protection against complement-mediated lysis
  • Lifespan intermediate between type1 and type 3 cells

Type III cells – red cells completely deficient in GPI-APs.

  • RBCs completely deficient in GPI-APs
  • No protection against complement-mediated lysis
  • RBC lifespan 10-15 days

  • Acute intermittent porphyria (AIP)
  • Hereditary coproporphyria (HCP)
  • Variegate porphyria (VP)
  • ALA-dehydratase deficiency porphyria (ADP)
  • Reduce rates of alloimmunization
  • Reduce rates of febrile nonhemolytic transfusion reactions
  • Prevent cytomegalovirus transmission
Meds, medications; MM, multiple myeloma; MDS, myelodysplastic syndrome; mets, metastases; DIC, disseminated intravascular coagulation.

Another perspective:

  • Mean cell volume (MCV)
  • Mean corpuscular hemoglobin (MCH)
  • Mean corpuscular hemoglobin concentration (MCHC)
  • Red cell distribution width (RDW)
From Pediatr Clin North Am. 2013;60:1349-62.
National Comprehensive Cancer Network (NCCN) and European LeukemiaNet (ELN) recommend WHO 2016 diagnostic criteria (above) for most accurate diagnosis. Hemoglobin thresholds for men and women were lowered in the 2016 revision to the WHO diagnostic criteria (16.5 g/dL for men or 16 g/dL for women) to include most cases of masked PV that were missed by the 2008 WHO criteria (18.5 g/dL for men and 16.5 g/dL for women).

Learn more here.

Helmet cells, keratocytes (horn cells), crescents, triangles, and microspherocytes. For more information see. Additional images shown here.

  • Eliminate precipitating factors
  • Treat patient’s symptoms
  • Reduce ALAS-1 activity and production of 5-aminolevulinic acid (ALA) and porphobilinogen (PBG) using:
    • Carbohydrate loading
    • Heme infusions

Thrombosis and disease progression to myelofibrosis or acute leukemia. Learn more here.

Homozygous sickle cell disease (HbSS), sickle beta0 thalassemia, sickle hemoglobin C disease, sickle beta+ thalassemia

From NHLBI 2014 clinical guideline

  • Thrombophlebitis
  • Coagulopathy
  • Hepatic iron overload (with chronic use)

Learn more here.

Acquired mutation in the X-linked phosphatidylinositol glycan class A (PIGA) gene in an hematopoietic stem cell. Leads to deficiency of  GPI-anchored proteins on hematopoietic cells, including CD55 and CD59, which in turn leads to  activation of the alternative complement pathway and complement-mediated hemolysis. Learn more here.

(A) In healthy subjects, GPI-anchored protein biosynthesis proceeds unperturbed in the endoplasmic reticulum. The full-length GPI anchor with attached protein (e.g., CD55 and CD59) resides in the membrane rafts of blood cells; thus red cells are protected from complement-mediated hemolysis. (B) In PIGA-PNH, a somatic mutation in PIGA  (required for the initial step in GPI-anchored biosynthesis) leads to failure to generate the GPI anchor in hematopoietic cells. After expansion of the PNH clone (often through immunologic escape) the PNH red cells are susceptible to complement-mediated hemolysis due to an absence of the GPI-anchored CD55 and CD59 from the cell surface. From RA Brodsky.

Aggregation of sickled cells, causing vaso-occlusion of small blood vessels, leading, in turn, to ischemia-reperfusion injury.

From Shutterstock, with permission

  • Conditions involving macrophage-mediated ingestion or red cells:
    • Hemophagocytic lymphohistiocytosis (HLH)
    • Pernicious anemia
    • Resorbing hematoma
  • Conditions not associated with red cell destruction:
    • Cirrhosis may also mimic hemolysis because the liver is responsible for synthesizing haptoglobin and hepatocytes release LDH and (especially in alcoholic liver disease) AST>ALT.
  • Iron levels
    • Iron increases hepcidin levels.
    • Represents a feedback mechanism to maintain stable body iron levels.
  • Inflammation 
    • Leads to increased hepcidin levels.
    • Represents a host defense mechanism to limit extracellular iron availability to microbes.
  • Erythropoiesis
    • Increased erythroid activity leads to decreased hepcidin levels.
    • Ensures iron supply for erythropoiesis.
    • Erythropoietic drive overrides both iron sensing and inflammation sensing mechanisms to control hepcidin levels.

Autoimmune hemolytic anemia

Acute intermittent porphyria

Direct antiglobulin test

Erythropoietin

Glucose-6-phosphate dehydrogenase. Learn more here.

Microangiopathic hemolytic anemia

Paroxysmal nocturnal hemoglobinuria

Packed red blood cells, used for transfusion.

Polycythemia vera

Red cell distribution width

Sickle cell anemia

Sickle cell disease

  • Hypochromic microcytic red cells
  • Pencil cells (reported in about two-thirds of cases)
  • Target cells
  • Fragments (in severe cases)
  • Thrombocytosis in some cases

Transferrin saturation. Represents the % of iron binding sites on serum transferrin that are bound by iron atoms.

Vaso-occlusive crisis, occurs in patients with sickle cell disease (SCD). The most frequent cause of recurrent morbidity and SCD-related admission to hospital.

Measured:

  • Hemoglobin (Hb)
  • Red blood cell (RBC) count
  • Mean cell volume (MCV)

Calculated:

  • Hematocrit (Hct) = MCV x RBC count
  • Mean corpuscular hemoglobin (MCH) = Hb/RBC count
  • Mean corpuscular hemoglobin concentration (MCHC) = Hb/Hct

In one study:

  • Normal platelet count in 84.6%
  • Thrombocytosis (> 400 × 10 9/L) in 13.3%
  • Thrombocytopenia (< 150 × 10 9/L) in 2.1%

They become smaller, they acquire a larger surface-to-volume ratio, they lose their organelles and the mean corpuscular hemoglobin concentration increases.

On Wright-Giemsa stained peripheral blood, reticulocytes have a purplish hue owing to the presence of residual RNA. These are called polychromatophilic cells (arrow).

British Society for Haematology recommends investigating patients with persistently elevated venous hematocrit (Hct) (> 52% in males and > 48% in females)

FDA test requirements (with American Red Cross guidance):

  • Hepatitis B virus (HBV):
    •  The tests used for blood donor screening are the GS HBsAg EIA 3.0, a qualitative ELISA for the detection of Hepatitis B Surface Antigen (HBsAg), and the Ortho HBc ELISA for the qualitative detection of antibody to HBV core antigen (anti-HBc) in human serum and plasma samples. 
    • An FDA licensed triplex nucleic acid test (NAT) using transcription-mediated amplification was introduced by the Red Cross in 2009. The assay detects HBV DNA, HIV-1 RNA, and HCV RNA. 
    • The frequency of detecting an active HBV infection in a blood donor is about 1 per 12,000 donations screened.
    • The per-unit risk of HBV infection through blood transfusion is less than 1 per million units screened. 
  • Hepatitis C (HCV):
    • The test used for blood donor screening is the Ortho HCV ELISA for the qualitative detection of antibody to HCV antibodies (anti-HCV) in human serum or plasma samples.
    • A duplex nucleic acid test (NAT) was introduced for HIV-1/HCV RNA detection in 1999 and updated to include the detection of HBV DNA in 2009.
    • Donors who test HCV-antibody reactive, but NAT nonreactive by routine testing are further tested individually for HCV RNA by NAT.
    • Donors who test anti-HCV and HCV NAT reactive do not require further testing. 
    • The frequency of detecting a positive donor is about 1 per 5,000 donations screened.
    • The per-unit risk of HCV infection through blood transfusion is less than 1 per 2 million units screened. 
  • HIV:
    • The test used for blood donor screening is the GS HIV-1/HIV-2 PLUS O EIA for the simultaneous qualitative detection of anti-HIV 1 (groups M and O) and/or HIV-2 in human serum or plasma. 
    •  A duplex nucleic acid test (NAT) was introduced for HIV-1/HCV RNA detection in 1999 and updated to include the detection of HBV DNA in 2009.
    • Donors who test antibody reactive are further evaluated by additional tests to confirm the presence of HIV antibody and to differentiate HIV-1 from HIV-2 antibodies. 
    • Donors who test anti-HIV-1/HIV-2 and HIV-1 NAT reactive are not further tested.
    • The frequency of detecting HIV-1 in a blood donor is about 1 per 33,000 donations screened.
    •  detecting HIV-2 in a blood donor is extremely rare at 1 per 57 million donations, with only 5 such infected donors ever identified since HIV-2 screening began in 1992.
    • The per-unit risk of HIV-1 infection through blood transfusion is less than 1 per 2 million units screened. 
  • Human T-cell lymphotropic virus I/II (HTLV-I/II):
    • The test used for blood donor screening is the Avioq HTLV-1/2 Microelisa system for the qualitative detection of antibodies to HTLV-1 and HTLV-2 in human serum or plasma samples.
    • Donors who test reactive for anti-HTLV-1/2 are further tested using an FDA licensed western blot to determine if antibodies are present. 
    • There are no nucleic acid tests (NAT) available for HTLV-1/2.
    • The per-unit risk of transfusion-transmitted HTLV-1/2 is less than 1 per 2 million units screened, and the frequency of detecting an infected donor is 1 per 27,000 donations screened.
  • Syphilis:
    • Screening for syphilis is performed using a qualitative test that detects the presence of antibodies to the spirochete (corkscrew-shaped bacterium), Treponema pallidum, by an automated agglutination assay based on specific pattern recognition. C
    • Confirmation is performed using another serologic test for total antibodies, an enzyme-linked immunoassay, as well as a test for reagin (a protein-like substance that is present during acute infection and for several months following resolution of infection). 
    • No cases of transfusion-transmitted syphilis have been recorded in more than 50 years. 
  • West Nile virus (WNV):
    • WNV RNA is detected by an FDA licensed NAT assay similar to that used for HIV-1, HCV, HBV, and Zika virus. 
    • NAT-reactive donations are further tested by repeat NAT and antibody to confirm infection. 
    • Following the introduction of blood donor screening, there have been 15 cases of transfusion transmission from screened blood; all are believed to be due to donations having very low levels of virus. This translates to a risk of about 1 per 84 million donations for the Red Cross overall (or 1 per 35 million during the summer transmission season). 
  • Trypanosoma cruzi:
    • The Red Cross blood donations are screened using the Ortho T. cruzi Enzyme-Linked Immunosorbent Assay (ELISA) for the qualitative detection of antibodies to T. cruzi in human serum or plasma samples.
    • An FDA licensed enzyme strip immunoassay (ESA) is used for confirmatory testing.
    • Because T. cruzi is not endemic in the United States, the Red Cross (and all US blood centers) donors are tested only once.
    • The frequency of detecting a positive donor is about 1 per 15,000 first-time donations screened.
  • Babesiosis:
    •  In May 2018, the Red Cross began testing from whole blood samples using a NAT assay that detects the main four species of babesia pathogenic to humans. The assay, now FDA licensed, detects ribosomal RNA of the parasite following red cell lysis, significantly increasing sensitivity and obviating the need for antibody testing.
    • Tested in 14 states in the US where incidence of infection is highest.

Refers to changes in quality and quantity of packed red blood cells (pRBCs) during storage, including:

  • Change in cell shape change and microvesiculation
  • Acidosis
  • Decrease in adenosine triphosphate (ATP) and 2,3-diphosphoglycerate levels
  • Increase in lysophospholipids
  • Increase in potassium
  • Increase in free Hb

The storage lesion represents a risk to efficient RBC perfusion and tissue oxygen delivery, and it has been suggested that it may result in adverse outcomes. This has led to the classification of “young” (21 days) RBC units. According to the AABB, 13 randomized control trials have evaluated the effect of RBC storage duration of transfused RBCs on patient outcomes (7 since 2012). However, there is currently no formal guidance on the optimal length of RBC storage prior to transfusion. The AABB recommends administering RBC units within licensed expiration date (standard issue) rather than transfusing only fresh RBCs (< 10 days old) to patients, including neonates.

Burr cells are red blood cells with 10-30 uniform, short, blunt projections distributed evenly around the circumference of the cell, giving the red cell surface a serrated appearance. The red blood cells retain central pallor. Seen in uremia, and to a lesser extent post splenectomy.

Echinocyte - Wikipedia
Scanning electron microscopy (SEM) of echinocytes (from Wikipedia)
Wright stained peripheral blood smear from a patient with end-stage kidney disease showing multiple burr cells.

A cold reactive antibody that causes agglutination without antiglobulin antisera at 4 degrees C (39.2 degrees F).

The first automated counters to hit the market was the Coulter counter, named after its inventor, Wallace H. Coulter. These
early counters used what is now known as the Coulter principle, which states that particles (for example a red blood cell) that
pass through an orifice with an electric current, produce a change in impedance that is proportional to the volume of the particle. That change is registered and recorded.

Serological or electronic crossmatch are performed to detect serological incompatibility (the presence of antibodies) between recipient and donor before transfusion.

AHG, anti-human globulin.

According to the AABB:

Defined as ≥ 1 degrees C increase in temperature ≥ 38 degrees C (100.4 degrees F) that is associated with transfusion and no other causes are evident. Caused by antibody to donor leukocytes. Symptoms include:

  • Fever
  • Chills
  • Tachypnea
  • Headache
  • Vomiting

According to the AABB, febrile nonhemolytic transfusion reaction defined as fever and/or chills without hemolysis occurring
in the patient during or within 4 hours of cessation of transfusion. If transfusion-related, the most common cause is a reaction to passively transfused cytokines or a reaction of recipient antibodies and leukocytes in the blood product. If blood culture of patient or residual component is performed, the results should be negative. Laboratory findings should show no evidence of
acute hemolysis.

Treatment includes antipyretic such as acetaminophen or meperidine (for more severe reactions).

Administer leukocyte-reduced blood or washed RBCs to reduce risk.

Howell-Jolly bodies are nuclear remnants in red blood cells, typically about 1 μm in diameter. As such, they are composed of DNA. Their presence indicates asplenia. Learn more about the history of discovery of the Howell-Jolly body here.

41% – 50% in male adults and 36% to 44% in female adults.

4.5-5.9 × 1012/L for male persons and 4.0-5.2 × 1012/L in female persons.

Note: 1012 = trillion!

On average about 1/3 of iron binding sites are occupied with iron atoms. Normal values, however, can range between 20-45%.

An abnormally shaped red cell

Poikilocytes include

  • Sickle cells (drepanocytes)
  • Burr cells (echinocytes)
  • Spur cells (acanthocytes)
  • Target cells (codocytes)
  • Spherocytes
  • Elliptocytes (includes pencil cells)
  • Stomatocytes
  • Bite cells
  • Tear drop cells (dacrocytes)
  • Schistocytes (includes helmet cells, horn cells, triangular cells, microspherocytes)
  • Fish-shaped red cells

In patients with intense erythropoietic stimulation, “young” basophilic reticulocytes are released prematurely from the bone marrow into the peripheral blood, causing shortened reticulocyte maturation time in the bone marrow (sometimes to < 1 day), but a longer reticulocyte maturation time in the peripheral blood. The RPI is a corrected reticulocyte count that accounts for reticulocytes in all development stages.

Reticulocyte production (maturation) index = reticulocyte count [%] × patient’s packed cell volume/0.45) / maturation time in peripheral blood.

Maturation time (days) varies according to Hct:

Hematocrit (%)Maturation correction
< 152.5
16-252
26-351.5
36-451

Reticulocyte production index of > 3 suggests normal bone marrow response to anemia while < 2 suggests inadequate response.

See calculator.

Immature, nonnucleated red blood cell (RBC) that circulates in the blood before losing their RNA and differentiating into mature RBC (the maturation process in the circulation takes 1-3 days). Reticulocytes are larger than mature RBCs, and contain intracellular organelles (with the exception of the nucleus).

Schistocytes, or schizocytes (from the Greek word schisto, broken or cleft) are circulating fragments of red blood cells or red blood cells from which cytoplasmic fragments have been lost. They lack central pallor and are often deeply staining. For more information see. Additional images shown here.

IV transfusion without removing patient blood volume.

A target cell is a red cell with centrally located disk of hemoglobin surrounded by an area of pallor with an outer rim of hemoglobin adjacent to the cell membrane giving the cell the appearance of a bull’s eye or shooting target. Seen in liver disease (macrocytic targets), iron deficiency anemia, thalassemia (microcytic target cells). Target cells may also be seen in hemoglobin C and E disease, and following splenectomy.

Peripheral smear showing multiple target cells (100x, oil)

Testing for presence of A and B antigens on red blood cells:

  • Forward typing – red blood cells (RBCs) are tested for A and B antigens.
  • Reverse typing – serum or plasma is screened for presence of anti-A and anti-B antibodies.

According to a Circular prepared jointly by AABB, the American Red Cross, America’s Blood Centers, and the Armed Services Blood Program:

The ABO group of all red-cell-containing components must be compatible with ABO antibodies in the recipient’s plasma. Serologic compatibility between recipient and donor must be established before any red-cell containing component is transfused. This may be accomplished by performing ABO/Rh typing, antibody screening, and crossmatching by serologic technique or use of a computer crossmatch.

ABO GroupPrevalence in US – European ethnicityPrevalence in US – African ethnicity
045%49%
A40%27%
B11%20%
AB4%4%
Prevalence of ABO Groups in the United States(
Interpretation of typing studies. From the AABB

Red cell mass > 25% above that predicted for sex and body mass.

Acanthocytes are densely stained, spheroidal red blood cells that lack central pallor and have 3-20 irregularly distributed, thorn-like projections of variable size/length/thickness, often with drumstick (knobby) ends. Spicules may occasionally have branches. Typically seen in cirrhosis, but also in hereditary abetalipoproteinemia and related neurological syndromes. Small numbers may be observed post-splenectomy.

Peripheral smear showing acanthocyte in middle of field
3D graphic of acanthocytes in blood (Shutterstock with permission)

Acute, severe reaction, typically caused by red blood cell ABO incompatibility.

According to the AABB, acute hemolytic transfusion reaction is defined as the rapid destruction of red blood cells during,
immediately after, or within 24 hours of cessation of transfusion. Clinical and laboratory signs of hemolysis are present.

According to the AABB, an allergic reaction is the the result of an interaction of an allergen with preformed antibodies. In some instances, infusion of antibodies from an atopic donor may also be involved. It may present with only muccocutaneous signs and symptoms.

Abrupt reduction in hemoglobin in a patient with sickle cell disease, typically caused by parvovirus B19-mediated suppression of red blood cell production.

ABO compatibility verified using computer system without immediate spin or and antiglobulin crossmatching if significant alloantibodies have not been detected in the recipient sample.

Using AABB guidelines, the electronic crossmatch is possible only if the following conditions are met:

  • The patient’s ABO group and Rh type has been done twice and entered in the computer (one group can consist of a record but one must be done on a current in-date specimen). * The computer must alert the technologist if there is a discrepancy between the two groups.
  • The donor ABO (and Rh types, if negative) have been confirmed and entered in the computer. The donor’s unit identification number, component name, and ABO/Rh type must also be entered in the computer (manually or by scanning the bar code label on the unit).
  • The computer system will alert the technologist to ABO & Rh discrepancies between information on the donor label and results of donor confirmatory testing.
  • The computer system will alert the technologist to ensure correct data entry and interpretation, e.g., prevent group O test results from being misinterpreted as group A.
  • The computer system will alert the technologist to ABO and Rh discrepancies patient and donor groups. The program should be programed to prevent assigning ABO incompatible blood (e.g., group A red cells to a group O recipient) and to give an alert when assigning Rh-positive red cells to Rh-negative recipients.

Mild-moderate decrease in serum hemoglobin (Hb rarely < 8 g/dL [80 g/L]), associated with acute or chronic inflammation, in which inflammatory mediators lead to increased hepcidin expression, iron sequestration and reduced erythropoiesis. Learn more here.

Defined as increased heterogeneity (or variation) in red blood cell (RBC) size, which can be measured as cell diameter (on a peripheral smear) or cell volume (using the red cell distribution width [RDW] generated by an automated counter).

Echinocyte

Drepanocyte

Dacrocyte

Spur cell

Burr cell

Chronic autoimmune atrophic gastritis

Acanthocyte

Anemia of inflammation

A rare, life-threatening disorder characterized by hypocellular bone marrow resulting in progressive pancytopenia (low reticulocyte, granulocyte, and platelet count) without bone marrow infiltrate dysplasia or fibrosis. See more here.

Itching of skin (often intense) that occurs within 30 minutes of contact with water. Characteristic symptom in polycythemia vera. Learn more here.

A debilitating dermal condition characterized by intense itching, stinging, tingling or burning sensations, without observable
skin lesions, precipitated by contact with water at any temperature. Typically occurs after a shower with warm water. Reported in 5%-69% of patients with polycythemia vera (PV) (41.2% of patients in a recent study of 102 patients with PV). Notably, the onset of aquagenic pruritus precedes diagnosis of PV in almost half of cases.

Congenital secondary erythrocytosis caused by mutations in oxygen sensing/hypoxia-inducible factor (HIF) signaling pathway (autosomal recessive mutations in VHL gene, a negative regulator of hypoxia sensing).

  • First hereditary condition of augmented hypoxia sensing to be recognized.
  • Autosomal recessive disorder with increased serum erythropoietin levels and hemoglobin concentrations in normoxia.
  • Hundreds of patients with Chuvash polycythemia are found in the Chuvash population of central Russia.
  • Mutation for Chuvash polycythemia is 598C>T in the von Hippel-Lindau gene (VHL) on chromosome 3p25.

Read more here.

Acquired uncompensated agglutination and premature destruction of red blood cells (RBCs) by autoantibodies (typically IgM) that target RBC antigens with optimal activity between 0 and 4 degrees C (32-39.2 degrees F), but also react at temperatures > 30 degrees C (86 degrees F). Learn more here.

British Committee for Standards in Haematology (BCSH) guideline suggests using serum cobalamin (vitamin B12) cutoff < 148 pmol/L (200 pg/mL) or cutoff derived from local reference range in patient with strong clinical suspicion for vitamin B12 deficiency. Learn more here.

Rare Diseases NIH: Autosomal dominant (rarely X-linked) inherited blood disorder that leads to anemia and is associated with physical abnormalities such as small head size (microcephaly) characteristic  facial features, cleft palate, cleft lip, short and webbed neck, small shoulder blades, and defects of the hands (mostly of the thumbs), as well as defects of the genitalia, urinary tract, eyes and heart. Caused by mutations in several genes. Learn more here.

A sickle cell. Some authors used to refer to sickle cell disease as drepanocytosis (for example, see this 1944 paper).

The EMA binding test uses flow cytometry to determine the amount of fluorescence (reflecting EMA bound to specific transmembrane proteins) derived from individual red cells. Red blood cells (RBCs) are incubated with EMA dye, which covalently binds to band 3 and other proteins on RBC surface. The mean fluorescence of EMA-stained RBCs in patients with hereditary spherocytosis is lower when compared with control RBCs due to the decreased amount of target proteins. The EMA binding test is easy to use, and test results are available for reporting in 2–3 h.

Read more here.

An increase in the number of red blood cells relative to the plasma volume. It is manifested by a persistent increase in the venous hematocrit:

  • Relative erythrocytosis – elevated hematocrit associated with normal red cell mass, resulting from contracted plasma volume most often due to dehydration.
  • Absolute erythrocytosis
    • An increased red cell mass above 125% of the predicted value for the body mass of the patient.
    • Red cell mass is rarely measured; hemoglobin and/or hematocrit typically used as surrogates s for red cell mass.

A vasomotor disturbance characterized by periodic attacks with triad of increased temperature, erythema, and burning pain resulting from hyperperfusion of skin areas, especially in the feet and hand. Typically relieved by cooling and aggravated by warming. May be primary or secondary. Causes of secondary erythromelalgia include polycythemia vera and essential thrombocythemia.

Learn more here.

A glycoprotein hormone secreted by peritubular cells in the kidney upon detection of reduced oxygen in the circulation. Binds to the erythropoietin receptor present on erythroid precursor cells in the bone marrow, resulting in stimulation of red blood cell production.

RBC, red blood cell; Epo, erythropoietin

Combined immune thrombocytopenia (ITP) and autoimmune hemolytic anemia. Learn more here.

Acute hemolytic anemia resulting from ingestion of fava beans. Learn more here.

Eculizumab or ravulizumab (C5 inhibitors). Learn more here.

Fluorescent aerolysin, used in flow cytometry to diagnose paroxysmal nocturnal hemoglobinuria (PNH) (selectively binds the GPI anchor with high affinity).

Flow cytometric analysis of granulocytes using FLAER. (A) As a control setting, there was no evidence of decreased (type II PNH cells) or absent (type III PNH cells) expression of FLAER. (B) In this patient, decreased (42.4%) and absent (57.0%) FLAER fractions were detected, suggesting that 99.4% of PNH granulocyte clones had a FLAER deficiency, which is consistent with classic PNH. Source.

A condition in which body iron stores are normal or increased, but iron incorporation into red cell precursors is impaired. One example is anemia of inflammation.

An X-linked genetic disorder caused by mutations in G6PD gene resulting in reduced activity of the G6PD enzyme. Learn more here.

Cureus | Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency Among  Children in Eastern Saudi Arabia

A 25-amino acid peptide hormone produced by liver hepatocytes in response to circulating iron levels which inhibits iron absorption from the intestinal mucosal cells and release by macrophages and hepatocytes through degradation of ferroportin-1. Hepcidin plays a critical role in iron absorption and recycling. Learn more here.

Hydroxyurea is a ribonucleotide reductase inhibitor

Ribonucleotide reductase, one of the most essential enzymes of life, and how it buries the RNA world Fcimb_04_00052_pdf_Page_1
From the following link.

Refers to the inability to produce adequate number of red blood cells in the presence of increased immature erythroid precursors.

Per Cazzola, M.:

  • In ineffective erythropoiesis, the erythroid marrow is active and expanded (erythroid hyperplasia) but its efficacy in terms of red cell production is impaired and may lead to anemia.
  • Erythroblasts are predominant in the bone marrow, and the M/E ratio is <1:1.
  • Ineffective erythropoiesis, is a major pathogenetic mechanism that is responsible for anemia in several inherited and acquired disorders, including:
    • Thalassemia:
      • Transfusion-dependent β-thalassemia (also known as β-thalassemia major) 
      • Nontransfusion-dependent β-thalassemia (also known as β-thalassemia intermedia; including β-thalassemia/Hb E) 
    • Inherited sideroblastic anemias 
    • Congenital dyserythropoietic anemias
    • Megaloblastic anemias 
    • Myelodysplastic syndrome 
  • Patients with ineffective erythropoiesis may have evidence of parenchymal iron overload, which derives from suppression of hepcidin production.

Lactate dehydrogenase (LDH) is a ubiquitous enzyme that catalyzes the conversion of lactate to pyruvate and back, resulting in conversion of NAD⁺ to NADH and back. LDH exists in five distinct forms, named LDH-1 through LDH-5, each having differential expression in different tissues:

  • LDH-1 is found primarily in heart muscle and red blood cells.
  • LDH-2 is the major isozyme of the reticuloendothelial system and red blood cells.
  • LDH-3 is highest in the lung.
  • LDH-4 is highest in the kidney, placenta, and pancreas.
  • LDH-5 is highest in the liver and skeletal muscle.
The red cell is a “fermenter“. It generates all of its energy from glycolysis without use of the Krebs cycle, yielding 2 molecules of ATP for very molecule of glucose. Instead of entering the Krebs cycle in the mitochondria (red cells do not have any mitochondria), pyruvate is metabolized to lactate via LDH.

Meets the criteria for diagnosis polycythemia vera despite lower-than-threshold hemoglobin/Hct.

Hemolytic anemia + schistocytes on the peripheral smear caused by high shear environment from partially occluded vessels or paravalvular jet streams. Note that MAHA Is often used to describe valve hemolysis, even though hemolysis occurs when red blood cells pass through paravalvular jet streams, not microvessels.

Free, unbound iron in the plasma. Consists of multiple chemical structures of iron (including labile plasma iron) associated with other plasma components. Typically appear when transferrin saturation > 70%. Rapidly taken up by parenchymal cells of the liver, heart, anterior pituitary cells and pancreas, where they generate reactive oxygen species and cause organ damage.

Learn more here.

Monitors the extent of red blood cell (RBC) shape change (elongation index) within a range of osmotic gradient under known shear stress and is a measure of hydration status of RBCs. Used to diagnose RBC membrane disorders.

The osmoscan module of LoRRca MaxSis is performed by adding 250 uL of whole blood to 5 mL of iso-osmolar polyvinylpyrrolidone (isoPVP). The diluted RBC suspension is submitted to an increasing osmotic gradient (from 80 mOsmol/L to 500 mOsmol/L) under a constant shear stress of 30 mPa. From Llaudet-Planas et al.

Read more here.

A form of pica, defined by eating of at least a tray of ice daily for 2 months or of ice chips. Learn more here.

A chronic myeloproliferative neoplasm associated with increased risk of thrombosis and bleeding, and disease progression to either myelofibrosis and/or acute leukemia. Caused by somatic mutations in JAK2 (Janus kinase), typically V617F.

A disorder of heme biosynthesis

Hematocrit > 51% lasting > 1 month post transplantation (usually develops within the first year post transplant). Occurs in 10%-15% of renal transplant recipients and is usually self-limiting. Most common after kidney transplant, but may also occur after other types of transplant, including hematopoietic stem cell transplantation. Learn more here.

A type of absolute erythrocytosis (increased red cell mass) caused by an intrinsic defect in the stem cell population leading to
autonomous proliferation of red cell progenitors within the bone marrow. There are two types of primary erythrocytosis:

  • Congenital erythrocytosis (primary familial or congenital polycythemia) caused by gain of function mutations in the erythropoietin receptor.
  • Acquired erythrocytosis (polycythemia vera) caused by a somatic mutation in the Jak2 gene.

A syndrome characterized by isolated normocytic normochromic anemia with severe reticulocytopenia and significant reduction or absence of erythroid precursors in bone marrow. Learn more here.

A trace byproduct of the last step in heme synthesis. In iron deficiency, zinc, instead of iron, is incorporated into the protoporphyrin ring, resulting in increased zinc protoporphyrin levels (iron protoporphyrin is also called heme). ZPP may be used as an assay for iron deficiency.

Heme synthesis from succinyl-CoA to PPIX and ultimately heme. Synthesis of ALA is the rate-limiting step and under negative feedback control of heme (green/ dashed). A deficiency of iron supply limits heme synthesis and leads to PPIX accumulation. Zinc can then substitute for iron and ferrochelatase catalyzes the formation of zinc PPIX (red/dotted). From the following link.

Elevated hematocrit associated with normal red cell mass resulting from contracted plasma volume most often due to dehydration.

  • Absence or presence of PNH clone
  • Clone size in red blood cells:
    • Total PNH clone size
    • Percentages of Type II and type III cells
  • PNH clone size in white blood cells:
    • Neutrophils
    • Monocytes

Learn more here.

Rouleaux is the arrangement of >3 red cells in a linear of branched pattern resembling a stack of counts. Seen in conditions associated with an inflammatory response and acute phase reaction or multiple myeloma.

Elevated red cell mass (absolute erythrocytosis) caused by a factor external from the bone marrow, typically erythropoietin (other factors include testosterone and cortisol). Learn more here.

A very small fraction of total ferritin circulates in blood. In contrast to its cellular counterpart, serum ferritin does not contain any iron and is almost entirely made up of L chains. It does not play a role in iron transport or cellular iron uptake. Indeed, its function is unknown. Serum ferritin is widely used as a convenient surrogate measure of body iron stores.

A group of chronic hemolytic anemias characterized by the presence of at least one hemoglobin S allele (HbS; p.Glu6Val in HBB) and a second HBB pathogenic variant leading to excessive production of hemoglobin S (HbS). Learn more here.

Screening for complement-activating alloantibodies in a patient who will receive a blood transfusion, using commercially available group O RBCs that express all antigens as required by the FDA.

Per the AABB:

Pretransfusion compatibility testing begins with the type and screen procedure. The recipient’s ABO group and Rh type are determined first; then a screening procedure is used to detect any unexpected non-ABO blood group antibodies that may be present. If the screening test reveals the presence of an antibody, the specificity of that antibody is determined by an antibody identification panel. Once the specificity of the antibody has been identified, donor units of the appropriate ABO group and Rh type are screened for the corresponding antigen. Units that are negative for that antigen are crossmatched with the recipient to ensure compatibility.

Antibody screening using an indirect antiglobulin test. Commercially available group O RBCs for antibody screening may be performed by 2 reagent single donor RBCs or 3 reagent single-donor RBCs. if antibody screen is positive, serum or plasma samples are tested against a panel of group O RBCs (typically 8-14 samples) with known antigenic composition to identify alloantibody specificity.

7.5 microns

Morphological Abnormalities of Red Blood Cells – The Art Of Medicine
Source

Partial deficiency of the third enzyme of heme synthesis, porphobilinogen deaminase (or hydroxymethylbilane synthase). It is an autosomal dominant condition.

Heme biosynthesis pathway

Autosomal dominant mutations of one of the following genes:

  • SPTA1 encoding alpha-spectrin
  • SPTB encoding beta-spectrin
  • EPB41 encoding protein 4.1
British Committee Standards in Haematology (BCSH) expert guideline on diagnosis of hereditary spherocytosis can be found in Br J Haematol 2012 Jan;156(1):37

Autosomal recessive mutations in one of the following genes:

  • SPTA1 (encoding alpha-spectrin)
  • SPTB (encoding beta-spectrin)
  • EPB41 (encoding protein 4.1)
British Committee Standards in Haematology (BCSH) expert guideline on diagnosis of hereditary spherocytosis can be found in Br J Haematol 2012 Jan;156(1):37

Autosomal dominant (75% of cases) or autosomal recessive (25%) mutations in genes that encode red blood cell (RBC) membrane proteins, resulting in qualitative defects of the encoded proteins. Genes with mutations include:

  • ANK1 encoding ankyrin
  • SLC4A1 encoding band 3
  • SPTA1 encoding alpha-spectrin
  • SPTB encoding beta-spectrin
  • EPB42 encoding protein 4.2

Mutations results in reduced binding of spectrin cytoskeleton to lipid bilayer of RBCs, leading to reduced membrane surface area (reduced surface area-to-volume ratio), reduced RBC deformability and increased osmotic fragility.

British Committee Standards in Haematology (BCSH) expert guideline on diagnosis of hereditary spherocytosis can be found in Br J Haematol 2012 Jan;156(1):37

Autoimmune-mediated atrophic gastritis, leading to deficient production of intrinsic factor (necessary for vitamin B12 absorption), and reduced vitamin B12 absorption. See more here.

Somatic mutations in JAK2 (Janus kinase), specifically V617F in exon 14 (reported in about 95% of patients) and mutations in exon 12 (reported in about 4% of patients), leading to constitutive activation of Jak2 signaling in hematopoietic stem cells.

Congenital gain-of-function mutations in erythropoietin receptor (EPOR)

Autoantibody, typically IgG, directed against red blood cell self-antigens with maximal reactivity at 37 degrees C (98.6 degrees F). Learn more here.

About 10%

  • Hemolytic anemia
  • Bone marrow failure
  • Thrombosis

Based on spectrophotometric measurement of cyanide derivative of hemoglobin.

Protocol includes:

  • Blood is mixed with a solution containing potassium cyanide and potassium ferricyanide (Drabkin’s solution).
  • The red blood cells are lysed, producing an evenly disturbed hemoglobin solution.
  • Potassium ferricyanide transforms hemoglobin into methemoglobin, and methemoglobin combines with potassium cyanide to produce hemiglobincyanide (cyanmethemoglobin).
  • Cyanmethemoglobin has a peak absorbance at 540 nm and is measured photometrically.
  • The absorbance is compared with that of the standard hemiglobincyanide solution by using a formula to obtain the amount of hemoglobin.

Hb<13 g/dL in men, Hb < 12 g/dL in women (<11 g/dL if pregnant)

Although the terms are often used interchangeably, they have slightly different meanings. Erythrocytosis is an increase in red blood cells (RBCs) relative to the volume of blood. Primary erythrocytosis is associated with an elevated red cell mass (a change in the numerator in RBC/volume), relative polycythemia is not (rather, it is a change in the denominator in RBC/volume). Polycythemia refers to increased red cell mass, manifested by increased Hct and/or hemoglobin, and usually caused by increased RBC count (erythrocytosis). In theory, an elevated MCV could produce increased red cell mass independent of RBC number (Hct=MVC x RBC count). As the name ‘poly’ implies, polycythemia more accurately refers to pan-myeloproliferation, but this definition is not normally adhered to.

Hb measures the total weight of hemoglobin contained within a given volume of blood. It is reported in g/dl or g/L. The Hct is the fractional volume of blood that is comprised of red cell cells. The Hct is expressed as a percentage.

A polychromatophilic cell is a red cell that is slightly larger than a mature red cell whose cytoplasm has a bluish tinge when observed on a normally stained peripheral smear. Most if not all of these cells correspond to reticulocytes, which are RNA containing red cells that are detected either with intravital stains (where blood is not fixed, but rather incubated alive with stain) or FACS analysis using an RNA fluorochrome. Reticulocyte staining is more sensitive than Wright-Giemsa staining for detecting reticulocytes: all true polychromatic cells are reticulocytes, whereas not all reticulocytes would be detectable as polychromatic cells.

Peripheral smear (Wright stained) showing polychromatophilic cell (arrow) (100X, oil)
Intravital stain of peripheral blood showing several reticulocytes, notable for their slightly larger size than mature red cells and presence of reticulin network within the cytoplasm. From Shutterstock with permission

Sickle cell anemia is a subset of sickle disease that includes the 2 most severe forms: homozygous sickle cell disease (HbSS), sickle beta0 thalassemia.

CAD, cold agglutinin disease; MDS, myelodysplastic syndrome; AA, aplastic anemia; MGUS, monoclonal gammopathy of unknown significance; MM, multiple myeloma; RBC, red blood cell; MCV, mean cell volume.

 1-4 mg/kg/day IV for 3-14 days based on clinical signs; do not exceed 6 mg/kg/day. Learn more here.

Erythrocyte sedimentation rate is the distance red cells fall by gravity in a vertical tube of anticoagulated whole blood. Learn more here.

From Shutterstock, with permission.

According to the AABB:

Each unit of RBCs contains enough hemoglobin to increase the hemoglobin concentration in an average-sized adult by approximately 1 gram/deciliter (g/dL) (increase hematocrit by 3%).

Involved in the biosynthesis of glycosylphosphatidylinositol (GPI) anchors, including CD55 and CD59.

Typically to maintain HbS level at < 30% immediately prior to next transfusion.

Fraction of whole blood that is made of RBCs (also known as packed cell volume).

Tube containing anticoagulated blood spun in a centrifuge. RBC, red blood cell.

G to T somatic mutation at nucleotide 1,849 in exon 14 of JAK2, leading to constitutive activation of signaling pathways downstream of the erythropoietin receptor. Learn more here.

G to T somatic mutation at nucleotide 1,849 in exon 14 of JAK2 causes valine to phenylalanine substitution at codon 617 (JAK2 V617F). Mutation located within the autoinhibitory pseudokinase domain of protein JAK2. Results in constitutive activation of STATs and thus EPO-independent signaling through the JAK-STAT pathway. May occur in:

  • Polycythemia vera (95% of cases)
  • Essential thrombocythemia (50-60% of cases)
  • Primary myelofibrosis (50-60% of cases)
  • Refractory anemia with ringed sideroblasts associated with significant thrombocytosis (50% of cases)

Jak2 V617F mutation is a G to T somatic mutation at nucleotide 1,849 in exon 14 of JAK2, leading to constitutive activation of signaling pathways downstream of the erythropoietin receptor. It occurs in 95% of patients with polycythemia vera as well as a smaller percentage of patients with other myeloproliferative neoplasms, encodes a constitutively active Janus kinase that upregulates JAK/STAT signal transduction, resulting in unregulated myeloproliferation (erythrocytosis, often with leukocytosis and/or thrombocytosis). Learn more here.

EPOR, erythropoietin receptor; FERM = N-terminal Band 4.1, ezrin, radixin, moesin domain; JH1 and JH2 = Jak homology 1 and 2 domains; SH2 = Src homology 2 domain.

Represents mean weight of hemoglobin (Hb) per red blood cell (RBC); calculated by dividing hemoglobin (Hb) by the RBC count (RBC).

HCH = Hb/RBC

Imagine drilling a hole in a single red blood cell and weighing the hemoglobin inside. Carry out this procedure on millions of cells, and calculate the average weight. That value is the mean cell hemoglobin!

Measures concentration of hemoglobin (Hb) per unit volume of red blood cells (RBCs); calculated by dividing hemoglobin (Hb) by hematocrit (Hct).

MCHC = Hb/Hct

Under normal conditions:
330 g/L = 150 g/L/0.45

The central white color represents the central pallor observed in RBCs on a Wright-Giemsa stained peripheral smear.

Defined as the value that describes the average size of red blood cells in a blood sample. Individual red blood cells may be microcytic, normocytic or macrocytic:

120 days

Crizanlizumab inhibits white blood cell-endothelial and platelet-endothelial interactions on blood vessel wall.

Overproduction of neurotoxic heme precursor from the liver caused by deficient enzyme in heme biosynthesis pathway, often in conjunction with precipitating factor that increases rate of heme synthesis.

Jak2 mutation (V617F)

Iron deficiency anemia, reported to account for about 50% of cases.

Vaso-occlusive crisis Learn more here.

Blood loss from the gastrointestinal tract

Menstrual blood loss

Hereditary spherocytosis; reported prevalence from 1 in 1,000 to 1 in 3,000 persons.

Babesia microti

80-100 fL

32-36 g/dL

At steady state, about 1%-2% of circulating red blood cells (RBCs) are reticulocytes, corresponding to an absolute reticulocyte count of approximately 25-100 × 109/L.

32-36 g/dL

80-100 fL

Measures red blood cell (RBC) lysis incubated in solution of varying concentrations of sodium chloride. RBC lysis is measured by detection of light absorbance by free hemoglobin immediately after sampling and after 24-hour incubation at 37 degrees C (98.6 degrees F). Osmotically fragile cells, such as spherocytes, lyse at relatively lower saline concentrations compared to normal RBCs.

Hypoxia-inducible factor 1-alpha (HIF1-alpha)

Measures proportion of RBCs that have a cellular hemoglobin weight of < 17 pg (analogous to the mean corpuscular hemoglobin, not mean corpuscular concentration - in other words, the term hypochromic is misleading). The parameter is available in some automated hematology analyzers. May be helpful for the assessment of iron availability (absolute or functional deficiency) for erythropoiesis.

A rare disorder associated with triad of:

  • Postcricoid dysphagia which is:
    • Typically painless, intermittent or progressive over years, and limited to solids
    • Occasionally associated with weight loss
  • Iron deficiency anemia
  • Upper esophageal webs

Anemia of inflammation (the anemia is not always chronic in nature)

0.01%-0.1%

5.4% in the United States, up to 80% in resource-limited countries. Learn more here.

Reported prevalence of anemia from all causes 33%-49% in patients with bariatric procedures (within 2 years after surgery). Learn more here.

12%-24% reported prevalence of anemia from all causes in patients with IBD. Learn more here.

Iron deficiency reported to occur in > 30% of patients after 5 years from surgery, with similar rate after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy. Learn more here.

Reported prevalence of iron deficiency in pregnancy 18%:

  • 7% in the first trimester
  • 30% in the third trimester

Learn more here.

Reported prevalence of iron deficiency approximately 1% in male adults and ≥ 11% in female adults. Learn more here.

Macrocytosis occurs in about 3% of the general population.

The variability in year of publication, statistical rigor, the mean cell volume (MCV) cutoff used to define macrocytosis and the different patient populations account for many differences in prevalence. The higher the MCV cutoff, the lower the prevalence of macrocytosis. Prevalence is higher with age. Most studies show higher prevalence of macrocytosis in males compared to females.

About 20%. Learn more here.

30-45% of patients

RBC transfusion at Hb level of < 7 g/dL (70 g/L) with a target Hb of 7-9 g/dL (70-90 g/L). Transfusion trigger should not exceed 90 g/L in most critically ill patients.

AABB recommendations in 2016:

For patients with stable cardiovascular disease who are hemodynamically stable, transfuse RBCs at Hb level of ≤ 8 g/dL (80 g/L).

AABB recommendations in 2016:

AABB recommendations 2022:

Consider treatment of symptomatic anemia with RBC transfusion to minimize symptoms; transfusion usually required when Hb is < 6 g/dL (60 g/L).

AABB (formerly, American Association of Blood Banks) recommends, for patients having orthopedic or cardiac surgery and are hospitalized and hemodynamically stable, transfuse at Hb level ≤ 8 g/dL (80 g/L).

AABB recommendations in 2016:

60-200 mg elemental iron /day in divided doses without food. Consider adding ascorbic acid (250-500 mg twice daily with the iron preparation) to maximize absorption, although there are no data for its effectiveness in the treatment of iron deficiency anemia.

JAMA. 2016;316(19):2025-2035.

Acute chest syndrome

Anemia of inflammation

> 24 hours after transfusion.

Within 24 hours of transfusion or during transfusion.

300 mL to 400 mL

According to the AABB:

Depending upon the collection system used, a single whole blood donation typically contains either 450 mL (+/- 10%) or 500 mL (+/- 10%) of blood collected from allogeneic blood donors. After plasma is removed, the resulting component is RBCs, which has a hematocrit between 65% to 80% and a usual volume between 225 mL and 350 mL. Red Blood Cells additive solutions (AS) may be mixed with the red cells remaining after removal of nearly all of the plasma to extend the shelf life (see Table 2). The typical hematocrit of AS RBCs is 55% to 65%, and the volume is approximately 300 to 400 mL.

Acute pulmonary edema due to volume overload from transfusion. Usual onset within 1-2 hours of transfusion. Risk factors include transfusion of large volumes of components or high flow rates. Treatment is supportive and may include lasix, and rarely therapeutic phlebotomy.

According to Nareg Roubinian: TACO is pulmonary edema primarily related to circulatory overload with criteria developed by the National Healthcare Safety Network including 3 or more of the following within 6 hours of transfusion:

  • Acute respiratory distress
  • Radiographic pulmonary edema
  • Elevated central venous pressure
  • Evidence of left heart failure
  • Elevated B-type natriuretic peptide (BNP)
  • Positive fluid balance

According to the AABB:

TACO is defined as new onset or exacerbation of 3 or more of the following within 12 hours of cessation of transfusion:

  • Elevated brain natriuretic peptide (BNP) or NT-pro BNP relevant biomarker.
  • Evidence of cardiovascular system changes not explained by underlying medical condition (Elevated central venous pressure, evidence of left heart failure including development of tachycardia, hypertension, widened pulse pressure, jugular venous distension, enlarged cardiac silhouette and/or peripheral edema).
  • Evidence of fluid overload.
  • At least 1 of the following:
    • Evidence of acute or worsening respiratory distress (dyspnea, tachypnoea, cyanosis and decreased oxygen saturation values in the absence of other specific causes) and/or,
    • Radiographic or clinical evidence of acute or worsening pulmonary edema (crackles on lung auscultation, orthopnea, cough, a third heart sound and pinkish frothy sputum in severe cases).
From Hematology Am Soc Hematol Educ Program. 2018;2018:585-594.

Form of acute lung injury caused by donor leukocyte antibodies (occasionally in recipient) and other leukocyte activating agents in plasma-containing components including whole blood, RBCs, platelets, cryoprecipitate, and fresh frozen plasma. Symptoms arise within 6 hours of transfusion and typically resolve after 48-96 hours. Treatment is supportive.

The Canadian Consensus Criteria defines TRALI as acute pulmonary edema after transfusion in the absence of circulatory overload or alternate acute respiratory distress syndrome (ARDS) risk factors:

According to the AABB, TRALI is defined as:

  • No evidence of acute lung injury (ALI) prior to transfusion, and
  • ALI onset during or within 6 hours of cessation of transfusion, and
  • Radiographic evidence of bilateral infiltrates, and
  • No evidence of left atrial hypertension (i.e., circulatory overload), and
  • Hypoxemia defined by any of these methods:
    • PaO2/FiO2 less than or equal to 300 mmHg
    • Oxygen saturation less than 90% on room air
    • Other clinical evidence

From Hematology Am Soc Hematol Educ Program. 2018;2018:585-594.

Increased iron intake sustained over a period of time as a result of multiple red blood cell (RBC) transfusions which may be exacerbated by increased absorption through the gastrointestinal tract.

Microhematocrit centrifugation is slightly higher owing to the effect trapped plasma.

First-line testing:

  • Complete blood count
  • Peripheral blood smear
  • Renal function
  • Liver function
  • Arterial oxygen saturation
  • Carboxyhemoglobin
  • Serum ferritin
  • Serum erythropoietin:
    • A low erythropoietin level (< 2.9 mU/mL) specific (92%) and moderately sensitive (64%) for the diagnosis of polycythemia vera.
    • A high erythropoietin level (> 15.1 mU/mL) specific (98%) but had poor sensitivity (47%) for the diagnosis of secondary erythrocytosis.
  • Jak2 mutational analysis (peripheral blood) – based on the pretest probability of polycythemia vera (PV):
    • In the primary care setting, where the probability of PV is low, clinical evaluation for secondary causes of erythrocytosis paired with a high erythropoietin level can rule out PV in most patients.
    • In hematology clinics, where the probability of PV is higher, erythropoietin level and JAK2 V617F mutation testing are done concurrently.
    • Patients with a low or normal erythropoietin level and no JAK2 V617F mutation are further evaluated with JAK2 exon 12 mutation testing (on peripheral blood or marrow aspirate, based on local practice) and a bone marrow biopsy

Second-line testing:

  • When no diagnosis is made, selected patients with onset of erythrocytosis at a young age or compatible family history should undergo testing for high-oxygen-affinity hemoglobins, and gene sequencing for mutations involving the erythropoietin receptor or oxygen-sensing pathways.
  • Investigations for secondary erythrocytosis should be symptom directed and may include:
    • Chest radiography
    • Overnight oximetry for suspected sleep apnea
    • Pulmonary function tests for hypoxic lung disease
    • Venous blood gas sampling (carboxyhemoglobin level)
    • Echocardiography to rule out right to left cardiac shunting
    • Abdominal–pelvic imaging can help exclude an erythropoietin-producing tumor or conditions associated with local renal hypoxia
    • Neuroimaging to rule out meningioma or cerebellar hemangioblastoma should be ordered for patients with unexplained neurologic symptoms as these tumors have been associated with autonomous erythropoietin production

Learn more here.

  • Electrical impedance (Coulter principle) 
  • Optical light measurements
    • Optical absorbance
    • Optical light scatter
    • Fluorescence
  • Cyanmethemoglobin measurement of hemoglobin

Morning

About 50%

About 70-80%

Reported mean daily iron absorption 6% for male adults and 13% for nonpregnant female adults in their childbearing years. Amounts to 1-2 mg/day (increasing to 6 mg in the third trimester of pregnancy).

One-third

10%-20% of patients. Learn more here.

>90% of such patients have evidence for a clonal expansion of kappa-positive B cells and a monoclonal IgM paraprotein. Learn more here.

About 1%

About 25%-35%. Learn more here.

About 30%

Iron deficiency is estimated to account for about 50% of all cases of anemia in pregnant and nonpregnant female adults.

20-25%

CXR, chest X ray.

Purple top tube, containing the anticoagulant EDTA (a powder sprayed on the wall of the tube).

IgM, reacting optimally between 0 and 4 degrees C. Learn more here.

Homozygous sickle cell disease (HbSS) and sickle beta0 thalassemia. Learn more here.

Both markers are highly sensitive, but MMA is more specific (for example, homocysteine levels may also be increased in patients with folate deficiency). MMA values considered high vary from 0.28 to 0.75 mcmol/L Learn more here.

Intrinsic factor antibodies are more specific (98-99% vs. 50%) but less sensitive (40-60% vs. 80-90%) than antiparietal antibodies. Learn more here.

In the mid-1950s when Wallace Coulter patented his technique for blood cell counting (termed the Coulter principle).

Learn more here.

Humans have no mechanisms to excrete iron. Iron is normally lost through:

  • Skin desquamation
  • Sweat – sweat contains up to 0.3 mg iron/L
  • Gut
  • Menstruation
  • Pregnancy

Anti-parietal cell antibodies, which target the gastric enzyme H+/K+ATPase proton pump. Learn more here.

Louis Diamond and Kenneth Blackfan, who first described the disorder in 1938 (Diamond LK, Blackfan KD. Hypoplastic Anemia. American Journal of Diseases of Children. 1938;56:464–467).

About 90% of cases reported in female adults, mean age at diagnosis of 47 years.

Robert S. Evans, first author on paper that first described the syndrome in 1951.

Because megaloblastic red cell precursors are destroyed in the bone marrow (ineffective erythropoiesis) and these immature cells contain hemoglobin, LDH and AST.

Because of residual RNA

Arrow, points to a polychromatophilic cell, which corresponds to a reticulocyte.

White blood cells

Lymphocyte count > 3.5-4.5 × 109/L

Absolute neutrophil count (ANC) ≤ 1.5 × 109/L in adults.

  • Mild 1-1.5 × 109/L; does not impair host defense.
  • Moderate 0.5-1 × 109/L; slight increased risk of infection if other arms of immune system also impaired.
  • Severe < 0.5 × 109/L; increased risk of infection in most patients.
  • Agranulocytosis ≤ 0.2 × 109/L; risk of severe, life-threatening infections.

Neutropenia reported to occur in up to 50% of patients with SLE.

1.6 billion leukocytes per kilogram body weight; more than half are neutrophils.

  • Arthralgia
  • Bone and back pain
  • Muscle spasms
  • Musculoskeletal pain
  • Pain in extremity
  • Splenomegaly
  • Epistaxis
  • Chest pain
  • Diarrhea
  • Hypoesthesia
  • Alopecia
  • Familial or congenital (rare)
  • Acquired
    • Primary (clonal)
      • Myeloproliferative neoplasms (MPN)
      • Myelodysplastic syndrome (MDS)
      • MDS/MPN overlap syndromes
      • Acute myeloid leukemia (AML)
      • Mastocytosis
      • Myeloid/lymphoid neoplasms with eosinophilia (rearrangement of PDGFRAPDGFRB, or FGFR1, or with PCM1-JAK2)Secondary (reactive)
    • Secondary (reactive)
      • Allergies
      • Helminth infections
      • Drug reactions
      • Autoimmune disorders
      • Cancer
      • Lymphocyte variant hypereosinophilia syndrome (HES)

Learn more here.

NAN, neonatal alloimmune neutropenia; NIN, neonatal isoimmune neutropenia,; SCN, severe congenital neutropenia; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis

Neutrophils, basophils, and eosinophils

  • Decreased production
  • Increased retention in bone marrow (decreased release into blood)
  • Increased migration to sites of inflammation
  • Increased apoptosis
  • Increased destruction and clearance by macrophages
  • Splenic sequestration

A group of chronic myeloid disorders characterized by hematopoietic stem cell-derived clonal myeloproliferation.

Neutrophils, basophils, and eosinophils

Learn more here.
Meds, medications; MM, multiple myeloma; MDS, myelodysplastic syndrome; mets, metastases; DIC, disseminated intravascular coagulation.

Another perspective:

  • Chronic myeloid leukemia (CML) (BCR-ABL1+)
  • Philadelphia chromosome-negative (BCR-ABL) MPN:
    • Polycythemia vera (PV)
    • Primary myelofibrosis (PMF)
      • PMF, prefibrotic/early stage
      • PMF, overt fibrotic stage
  • Essential thrombocythemia (ET)
  • Chronic neutrophilic leukemia (CNL)
  • Chronic eosinophilic leukemia, not otherwise specified (NOS)
  • MPN, unclassifiable

Learn more here.

Chronic myelogenous leukemia; polycythemia vera; primary myelofibrosis; essential thrombocythemia; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified (NOS); MPN, unclassifiable.

Dohle bodies, toxic granulation and vacuolization

Reactive (secondary):

  • Viral, bacterial, or parasitic infection
  • Vaccinations
  • Connective tissue disease
  • Smoking
  • Postsplenectomy state

Clonal (primary):

  • Chronic lymphocytic leukemia (CLL)
  • Certain B-cell and T-cell leukemia/lymphomas

Reactive (secondary):

  • Viral or bacterial infection
  • Corticosteroids
  • Malignancy
  • Postsplenectomy state
  • Autoimmune disorders (such as inflammatory bowel disease or sarcoidosis)
  • Vasculitides

Clonal (primary):

  • Monocytic leukemia
  • Chronic myelomonocytic leukemia
  • Mastocytosis

Myelodysplastic syndrome

Myeloproliferative neoplasm

Differential of neutrophils, eosinophils, basophils, lymphocytes, and monocytes, typically performed by modern automated hematology analyzers.

A band neutrophil is a young neutrophil with deeply indented nucleus. The nucleus is indented to more that half the distance to the farthest nuclear margin. Chromatin is consistently present between edges of nuclear membrane, but in no area is it condensed to a single filament. Normally comprise < 10% of circulating white cells. Increased numbers in left shift (as occurs with inflammation and infection) and myeloproliferative neoplasms.

From Shutterstock, with permission
Peripheral smear showing band neutrophil in center. From Shutterstock, with permission

Döhle bodies appear as single or multiple blue or gray-blue inclusions of variable size (0.1 to 5.0 μm) and shape (round or elongated or crescent shaped) in the cytoplasm of neutrophils, bands, or metamyelocytes. They are often found in the periphery of the cytoplasm, near the cell membrane. Seen in conditions associated with increase cytokine release such as infection, burns, trauma, and administration of G-CSF.

Peripheral smear showing Dohle body (arrow) in a neutrophil

A leukemoid reaction is defined by a leukocyte count greater than 50,000 cells/μL, caused by reactive causes outside the bone marrow. Learn more here.

4-11 x 109/L

Smudge cells are remnants of fragile lymphocytes that are generated during preparation of peripheral smear. They lack any identifiable cytoplasmic membrane or nuclear structure. They contain dense nuclear material and or chromatic strands. They are characteristic of chronic lymphocytic leukemia.

Peripheral smear showing smudge cell

Neutropenia that is acquired in adulthood but eludes a specific diagnosis is termed chronic idiopathic neutropenia (CIN). It is a diagnosis of exclusion that can only be made after a thorough and unrevealing search for other causes, including negative testing for autoimmune disease and nutritional deficiency and a normal bone marrow examination with normal cytogenetics. Its pathogenesis is unknown.

Learn more here.

Benign, stable course often in middle-aged women with rare evolution to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Diagnosis of exclusion. Term is often used synonymously with autoimmune-mediated neutropenia since there are no definitive tests to diagnose the latter.

Mild, chronic neutropenia, usually with an ANC >1000 in a patient with no history of recurrent infections. Constitutional neutropenias are more common in patients of certain ethnic backgrounds, particularly those of Mediterranean and African descents.

Cyclic neutropenia (CN) is a rare autosomal dominant disease characterized by episodes of self-limited neutropenia that recur every 2 to 5 weeks. The cycles are of varying length but are very consistent within each patient. Unlike SCN, there is no increased risk of developing AML. CN results from mutations in ELANE.

Learn more here.

Persistent blood eosinophil count >1.5 x 109/L (on 2 examinations over ≥ 1 month without evidence of organ damage). Learn more here.

White blood cell count (WBC) > 100 x 109/L, usually seen in leukemias and myeloproliferative disorders, though may rarely occur as a reactive condition.

TermDefinition
LeukocytosisWhite blood cell (WBC) count > 11 × 109/L.
Leukemoid reactionIncreased WBC count (typically > 50-100 × 109/L) that occurs in response to reactive causes.
HyperleukocytosisWBC > 100 × 109/L, usually found in leukemias and myeloproliferative disorders.
LeukoerythroblastosisImmature neutrophil precursors (with or without leukocytosis) and nucleated red blood cells in peripheral blood, indicative of severe disruption of the marrow by overwhelming infection, myelofibrosis, or bone marrow invasion due to malignancy.

Immature neutrophil precursors – in absence or presence of elevated white count – and nucleated red blood cells (RBCs) in the peripheral blood, indicative of severe disruption of the marrow by overwhelming infection, myelofibrosis, or bone marrow invasion due to cancer. Tear drop shaped RBCs are also often present. Learn more here.

Intravascular accumulation of white blood cells (WBCs) causing obstruction of blood flow in patients with hyperleukocytosis (defined as WBC count >100 x 109/L), especially those with acute leukemia, in which the white cells are “stickier” compared to reactive causes or those with chronic lymphocytic leukemia (CLL). May lead to organ compromise. Learn more here.

A heterogeneous group of clonal disorders characterized by ineffective hematopoiesis leading to peripheral blood cytopenias and an increased risk of transformation to acute myeloid leukemia.

Reactive (polyclonal) eosinophilia secondary to malignancy

  • A group of inherited disorders characterized by agranulocytosis and recurrent, severe infections that begin during infancy.
  • 10% to 30% lifetime risk of developing acute myelogenous leukemia.
  • A heterogeneous syndrome, caused by inherited mutations in several neutrophil-specific genes, most commonly the primary granule protein gene neutrophil elastase (ELANE).

learn more here.

Associated with null polymorphisms in Duffy antigen receptor complex (DARC) gene. Duffy null polymorphism associated with protection against invasion of red blood cells by Plasmodium vivax malaria. Mechanism of lack of DARC and associated neutropenia unknown.

Autosomal dominant disorder usually caused by mutation in primary granule protein gene elastase, neutrophil expressed (ELANE, formerly ELA2), which encodes neutrophil elastase.

  • Autosomal dominant causes include mutations in:
    • ELANE
    • GFI1, which encodes transcriptional repressor oncoprotein GFI1 thus repressing CEBPACEBPE and ELANE, important regulators of myeloid differentiation and neutrophil function
    • CSF3R
  • Autosomal recessive causes include mutations in:
    • HAX1, which encodes an antiapoptotic gene (also called Kostmann syndrome)
    • G6PC3, which encodes a neutrophil-specific catalytic subunit of glucose-6-phosphatase
    • VPS45
    • JAGN1
    • CSF3R
  • Unidentified genetic cause in up to 30% of SCN patients.

Basophil count > 0.1 x 109/L

White cell count > 11 x 109/L

Monocyte count > > 0.8-1.0 × 109/L

Neutrophil count > 7-7.7 × 109/L

Reactive (secondary):

  • Drug reactions
  • Allergy/hypersensitivity reaction
  • Infections (especially tissue-invasive parasites, such as strongyloides)
  • Cancer
  • Sarcoidosis
  • Connective tissue diseases
  • Adrenal insufficiency
  • Pulmonary diseases such as eosinophilia pneumonia

Clonal (primary):

  • Chronic eosinophilic leukemia
  • Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRAPDGFRB, or FGFR1, or with PCM1-JAK2
  • Other acute and chronic primary bone marrow processes such as myeloproliferative neoplasms

Reactive (secondary):

  • Infection
  • Chronic inflammation
  • Smoking
  • Stress
  • Obesity
  • Drugs, for example:
    • Corticosteroids
    • Beta-agonists
    • Lithium
    • Epinephrine
  • Endocrine disorders:
    • Hypercortisolism
    • Thyroid storm
    • Pre-eclampsia
  • Post-splenectomy state
  • Bone marrow stimulation
  • Nonhematologic malignancy
  • Inherited disorders

Clonal (primary):

  • Chronic neutrophilic leukemia
  • Chronic myelogenous leukemia
  • Essential thrombocytosis (ET)
  • Polycythemia vera
  • Blood eosinophilia is defined as peripheral blood eosinophil count > 0.5 × 10 9/L.
  • Blood hypereosinophilia is persistent eosinophil count > 1.5 × 109/L on 2 examinations over ≥ 1 month without evidence of organ damage.
  • Hypereosinophilic syndrome is hypereosinophilia of any cause (reactive or clonal) associated with clear evidence of hypereosinophilia-related organ damage.

Learn more here.

  • Defined as immature neutrophil count (myelocytes + metamyelocytes + promyelocytes)/total neutrophil count.
  • Used as an indicator of a granulocyte left shift.

Toxic granulation is the presence of large purple or dark blue cytoplasmic granules (primary granules) in neutrophils, bands, and metamyelocytes. The granules have increased staining density compared to normal neutrophils. Seen in conditions associated with increase cytokine release such as infection, burns, trauma, and G-CSF administration.

Platelets

Typically 5-10 days. Learn more here.

Yes, especially in primary thrombocytosis, because platelet glycoprotein 1b binds to circulating von Willebrand factor, leading to acquired von Willebrand syndrome.

No, the pathogenesis of iron deficiency-associated thrombocytosis is unclear, but may involve increased commitment of bipotential (erythroid/megakaryocytic) progenitor cells to the megakaryocytic lineage. Learn more here.

Yes, they are 20-25% lower in individuals with type O blood group. 14% of individuals with type O blood have vWF levels ≤ 50 units/dL. Learn more here.

<30 x 109/L according to 2019 ASH guideline:

<20-30 x 109/L according to International Consensus Report:

ADAMTS13 activity level

No. In unconfirmed atypical HUS, serum/plasma complement factor levels may suggest diagnosis but they are unreliable as direct diagnostic tests.

Yes, and in fact they are now recommended as an option in the latest American Society of Hematology (ASH) guideline, especially for those who are not at high risk of bleeding and who do not have extensive clot burden.

At minimum, all critically ill non-bleeding patients with DIC should receive prophylactic anticoagulation for venous thromboembolism.

Regarding therapeutic doses of heparin, the 2013 ISTH harmonization guideline states:

Anticoagulant treatment may be a rational approach based on the notion that DIC is characterized by extensive activation of coagulation. Although experimental studies have shown that heparin can at least partly inhibit the activation of coagulation in DIC, there are no RCTs demonstrating that the use of heparin in patients with DIC results in an improvement in clinically relevant outcomes… therapeutic doses of heparin should be considered in cases of DIC where thrombosis predominates (low quality evidence). The use of low molecular weight heparin (LMWH) is preferred to the use of unfractionated heparin (UFH) in these cases (low quality evidence).

Yes! Proposed mechanisms include:

  • Formation of platelet-white cell complexes
  • Direct effect of pathogens on platelet activation and aggregation
  • Hemophagocytosis
  • Reduced platelet production

Learn more here.

Patients with type 2B vWD may have thrombocytopenia. Learn more here.

No, they are not different between the two conditions.

No significant difference in thrombopoietin (TPO) levels was found between the two groups of patients, indicating that serum TPO levels cannot differentiate between primary and reactive thrombocytosis. No significant correlation was found between platelet count and TPO levels in either ET-PV or reactive thrombocytosis. Source.

Learn more here.

Caplacizumab does not affect ADAMTS levels or ADAMTS13 antibody production. It is an anti–von Willebrand factor humanized, bivalent variable-domain-only immunoglobulin fragment that inhibits interaction between von Willebrand factor multimers and platelets.

Yes, it is much more common in later stages of cirrhosis (about 5% prevalence with I-IV fibrosis vs. 65% in patients with stage III-IV fibrosis). Learn more here.

CCI = posttransfusion count increment (CI; posttransfusion platelet count – pretransfusion platelet count) × body surface area (in m2)/number of platelets transfused

See calculator.

Posttransfusion platelet count – pretransfusion platelet count

By apheresis or from whole-blood by platelet-rich plasma or buffy coat methods.

They are pinched off from proplatelet tips and released into the circulation. Learn more here.

They are stored in gas-permeable storage bags with gentle agitation at 20-24 degrees C (68-75.2 degrees F).

2-4 × 0.5 micrometers with mean volume of 7-11 fL.

15%-20% of patients presenting with acute lymphoblastic leukemia, > 90% of patients presenting with acute promyelocytic leukemia.

About 1%

Over 95% of patients with DIC have thrombocytopenia.

Occurs in about 50-60% of such patients.

About 8%-68% of patients at time of admission, up to 50% of patients during stay in ICU. Learn more here.

Thrombocytosis occurs in about 10-15% of patients with iron deficiency anemia. Learn more here.

They block platelet aggregation by inhibiting fibrinogen binding to glycoprotein GPIIb/III on the platelet surface.

DDAVP 0.3 mcg/kg IV in 30-50 mL normal saline over 30 minutes. May be repeated 12-24 hours after first dose, depending on how well the patient responds, but no more than 2-3 doses should be given in order to avoid tachyphylaxis.

Decrease platelet clearance and increase platelet production. Also, steroids may reduce bleeding, independent of their effect on platelet counts, by a direct stabilizing effect on blood vessels. Learn more here.

1 unit vWF:RCo/kg infused will result in recovery of 1.5-2 units vWF:RCo/dL in adults; 50 units vWF:RCo/kg will give a recovery of 75-100 units vWF:RCo/dL.

Direct toxic effect on the bone marrow. Learn more here.

Aspirin inhibits cyclooxygenase 1 (COX1), thereby decreasing production of thromboxane A, a major mediator of platelet activation.

DDAVP increases the release of vWF and factor VIII from endothelial cell stores by releasing vWF from cytoplasmic organelles called Weibel-Palade bodies.

Removes autoantibodies and replenishes ADAMTS13 levels.

Rarely below 30-40 × 109/L

70%-80% of cases

Thrombosis occurs in one-third to one-half of patients with HIT. It may occur in veins, arteries or microvessels.

Platelet count < 100 × 109/L in absence of other causes of thrombocytopenia.

From the 2019 International Consensus Report

aPTT; adjust to 1.5-3.0 times baseline.

aPTT; adjust to 1.5-2.5 times baseline.

DDAVP may be administered IV, subcutaneously, or by nasal spray.

No one laboratory test is specific for DIC. Clinical practice guidelines recommend using a clinical scoring system, such as the ISTH scoring system, which includes consideration of the platelet count, D-dimers, fibrinogen and the prothrombin time.

Based on clinical presentation (thrombocytopenia and/or thrombosis in temporal association with heparin therapy without other obvious causes) plus presence of platelet-activating antiplatelet factor 4 (PF4)/heparin antibodies. Clinical prediction scores, especially the 4T score, are helpful in estimating the pretest probability of HIT and determining whether heparin should be discontinued and if further testing for antibodies should be carried out.

Based on clinical presentation (thrombocytopenia and/or thrombosis in temporal association with heparin therapy without other obvious causes) plus presence of platelet-activating antiplatelet factor 4 (PF4)/heparin antibodies.

Low Corrected Count Increment (CCI) < 1 hour after transfusion suggests immune-mediated platelet refractoriness. Most studies define refractoriness as a CCI of <5,000 after 2 sequential transfusions. However, a CCI of <7,500 or a PPR of <30% are also accepted values. Read more here.

Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):527-532




Nonimmune mediated refractoriness is indicated if normal Corrected Count Increment (CCI) < 1 hour after transfusion, followed by low CCI at 18-24 hours after transfusion. Read more here.

Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):527-532




2019 Guidelines on the Use of Therapeutic Apheresis in Clinical Practice: “[Plasma exchange] is generally performed daily until the platelet count is >150 × 109/L, and LDH is near normal for 2-3 consecutive days. The role of tapering TPE over longer duration has not previously been studied prospectively but is currently being reviewed. A small retrospective study suggests a lower overall recurrence rate at 6 months with taper. A common taper strategy is three times a week for the first week, twice weekly the second and then once weekly the following week(s). Other taper approaches have been documented.”

Options include increased frequency of plasma exchange, rituximab, and immunosuppressive therapies such as cyclophosphamide and vincristine.

Primary (clonal) and secondary (reactive)

Classification of thrombocytosis. ET, essential thrombocythemia; MDS, myelodysplastic syndrome; TPO, thrombopoietin.

Platelet count > 450 × 109/L

≤ 5 days in the United States; however, most blood collection centers culture apheresis platelets and release the unit 24-36 hours after collection.

4-8 weeks, including taper.

The 2019 ASH clinical guideline recommends treating for 6 weeks or less:

The 2019 International Consensus Report suggests a maximum of 8 weeks:

About 12 million in the United States!

About 1011 (by contrast, about 200 billion [200 x 109] red cells are released into the circulation every day)

1 apheresis platelet unit is equivalent to a pool of 4-6 units of whole blood-derived platelets; typically contains ≥ 3 × 1011 platelets.

About 5000.

Summary of 47 platelet proteomics studiesA, Platelet proteomics has been used to characterize the global proteome, specific subproteomes, activity-based protein profiling (ABPP), and post-translational modifications (PTM). B, These studies are mainly (40%) based on 2-dimensional gel electrophoresis (2-DE)/difference gel electrophoresis (DIGE),whereas gel-free methods (23%) are still under-represented. Combination refers to studies using 2-DE/DIGE in combination with other approaches. COFRADIC indicates combined fractional diagonal chromatography; and MudPIT, multidimensional protein identification technology. Source.

Learn more here.

As of 2021, there are 27 known forms arising from mutations in 31 genes! Learn more here.

Three: Type 1, type 2, and type 3

From Leebeek and Eikenboom

The current classification includes types 1 and 3, which are characterized by quantitative deficiencies of von Willebrand
factor (VWF), as well as types 2A, 2B, 2M, and 2N, which are qualitative variants.

Three main types:

  • Type 1
  • Type 2, with the following subtypes:
    • 2A
    • 2B
    • 2M
    • 2N
  • Type 3
Journal of Thrombosis and Haemostasis, 4: 2103–2114

10-20% of patients

If the patient has primary thrombocytosis (for example, essential thrombocythemia), they are at higher risk of thrombosis (though the risk does not correlate well with the platelet count). In patients with secondary or reactive thrombocytosis, there is no compelling evidence supporting an increased risk of thrombosis. Indeed, if anything, they may be at increased risk for bleeding owing to acquired von Willebrand syndrome (though this is far less common in secondary compared with primary thrombocytosis).

Once the platelet count is over 150 x 109/L, switch to warfarin (with appropriate overlap) or preferably to a DOAC (see 2018 American Society of Hematology [ASH] guideline recommendation 3.9 below). In case of HIT without thrombosis, continue for no longer than 3 months (typically 4-6 weeks). In the case of HIT complicated by thrombosis (termed HITT), treat for 3-6 months (see ASH guideline recommendation 3.8 below).

Subacute HIT A is the phase following platelet count recovery but before the functional assay becomes negative. See 2018 ASH guideline.

May be repeated up to 3 times, according to the 2019 International Consensus Report:

Even with platelet count recovery, patients remain at risk for thrombosis for 4 to 6 weeks after diagnosis (~17–53% over a thirty day period) because of circulating anti-PF4/heparin antibodies. While there is consensus among experts that patients with isolated HIT should be treated in the short-term with alternative anticoagulants, there is no firm consensus on the intensity or duration of anticoagulation for this patient population.

Platelet count recovery occurs within 7 days in 90% of cases. Functional assays become negative at a median of 50 days after heparin is suspended, while circulating anti-PF4/heparin antibodies are no longer detectable by immunoassay at a median of 85 days.

Median 50 days for platelet activation assays and 85 to 90 days by immunoassays.

No. For patients who have received heparin in the last 100 days, thrombocytopenia can develop rapidly (median = 10.5 hours), due to circulating PF4/H antibodies. However, patients who are re-exposed to the drug months to years after antibody disappearance do not manifest anamnestic responses, and seroconversion risk appears similar to de novo heparin exposure.

21-33 days postoperatively at median platelet count of 700 × 109/L before stabilizing after 45 days.

First heparin exposure

Highest platelet count that immediately precedes the putative HIT-related fall in platelet count.

  • < 72 hours post-surgery
  • Infection (confirmed bacteremia/fungemia)
  • Chemotherapy or radiation < 20 days
  • Disseminated intravascular coagulation (DIC)
  • Posttransfusion purpura
  • Other drugs implicated in drug-induced thrombocytopenia

No. There are 4 parameters that are used in clinical scoring systems for DIC: fibrinogen, prothrombin time (PT), platelet count and D-dimers/fibrin degradation products. Fibrinogen is the least sensitive of these markers (overall sensitivity of low fibrinogen level reported to be 28%) because it is an acute phase reactant and therefore often elevated in conditions associated with DIC.

No, it is a complication of an underlying diseases such as sepsis or cancer.

Yes, in about 50% of cases. Learn more here.

No

No, there is no evidence that it is. Learn more here.

No. Platelet-associated IgG is elevated in both immune and nonimmune thrombocytopenia and assays for antibodies to specific platelet glycoproteins, while quite specific, have poor sensitivity. Clinical practice guidelines do not recommend ordering the test.  

From 2019 International Consensus Report

The aPTT may be increased in Type 2N vWD (the mutation specifically impairs the ability of vWF to carry FVIII) and Type 3 vWD (since vWF carries and stabilizes FVIII in the circulation, the very low levels of vWF associated with Type 3 vWD result in low FVIII activity).

Yes, It’s called Vonvendi.

Yes, treatment with plasma exchange should begin as soon as possible, preferably within 4-8 hours of initial clinical diagnosis.

British Committee for Standards in Haematology guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
British Committee for Standards in Haematology guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies

Not in patients with a typical presentation of ITP.

2019 ASH clinical guideline

Antiplatelet therapy is not recommended, even in patients with extreme thrombosis, due to lack of evidence for thrombotic risk and theoretical risk of paradoxical bleeding from acquired von Willebrand syndrome. In cases where thrombosis has been reported in patients with reactive thrombocytosis, it is not known whether elevated platelet counts are causal or simply a marker of underlying disease with high thrombotic risk. Learn more here.

Yes, bilateral dopplers of the lower extremities are recommended in patients with acute isolated HIT.

Only if the patient has an upper-extremity central venous catheter, or has signs or symptoms suggestive of upper extremity DVT.

In a randomized trial, high-dose dexamethasone (40 mg daily x 4 days) was shown to lead to a faster response compared to prednisone, and without additional toxicity. However there was no difference in platelet count response at 6 months. Consider dexamethasone if quick response is particularly important, for example in a patient who is bleeding or needs to have surgery.

The following data are from the randomized trial mentioned above. The captions speak for themselves:

Guideline recommendations:

No, not unless there is another indication for these drugs, for example a coronary stent, and provided the risk: benefits are acceptable.

No, platelet transfusions may exacerbate the thrombotic tendency in HIT. Platelet transfusion should be reserved for patients with active bleeding or at high risk of bleeding.

2018 ASH guideline

Consider admission to hospital of patients with platelet < 20 x 109/L, even if they are asymptomatic.

 No, not unless there is life-threatening bleeding.

From Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura

It may be considered once the platelet count increases to a safe level (e.g., > 50 x 109/L), but there is no evidence of clinical efficacy in this setting.

From Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura
  • Reduce rates of alloimmunization
  • Reduce rates of febrile nonhemolytic transfusion
  • Prevent transmission of intracellular pathogens such as:
    • cytomegalovirus (CMV)
    • human T-lymphotropic virus
    • types I and II (HTLV- I/II)
  • Immunoassays that detect presence of antibodies to platelet factor (anti-PF4/heparin antibodies).
  • Functional assays – such as the serotonin release assay – that detect anti-PF4/heparin antibodies capable of activating platelets.

  • Argatroban
  • Bivalirudin
  • Danaparoid
  • Fondaparinux – especially in clinically stable patients at average risk of bleeding, and provided normal renal function.
  • DOAC:
    • Especially in clinically stable patients at average risk of bleeding.
    • Most of the published experience in HIT is with rivaroxaban.
Effectiveness and safety outcomes of various anticoagulants used in the treatment of HIT. Pooled proportions of (A) platelet recovery, (B) thromboembolism, (C) major bleeding, and (D) death are shown according to the treatment scheme. The logit-transformed proportions were pooled using a random-effects model based on a random intercept logistic regression model. Groups, number of treatment groups; 95% CI, 95% confidence interval; n, number of patients. Confidence intervals were mostly overlapping, and results were not influenced by patient population, diagnostic test used, study design, or type of article. Source.
  • Immune-mediated
    • Alloimmunization to human leukocyte, platelet-specific, or ABO antigens
    • Autoimmune (immune thrombocytopenia)
  • Non-immune-mediated
    • Hemorrhage
    • Fever
    • Sepsis
    • Disseminated intravascular coagulation (DIC)
    • Splenic sequestration
    • Use of older stored platelets
    • Thrombotic microangiopathy

Essential thrombocythemia, polycythemia vera, primary myelofibrosis, CML, MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T), CMML and myelodysplastic syndrome with del (5q)

Aminocaproic acid and tranexamic acid

Quinine, quinidine, trimethoprim/sulfamethoxazole, and vancomycin (heparin-induced thrombocytopenia is considered separately).

  • von Willebrand factor antigen (vWF:Ag)
  • von Willebrand factor ristocetin cofactor activity (vWF:RCo) (platelet-binding activity of vWF measured by vWF:RCo assay)
  • Factor VIII activity (FVIII:C)
  • von Willebrand factor collagen binding (vWF:CB) activity (recommended by BCSH but not NHLBI as first-level test)
  • Transfusion-associated graft-versus-host disease
  • Immunocompromised patients
  • Hematologic malignancies or certain solid tumors
  • Recipients of marrow or peripheral blood stem cell transplantation
  • Patients receiving blood components from blood relatives or human leukocyte antigen-compatible donors
  • Patients receiving fludarabine therapy
  • Prematurity, low birthweight, or erythroblastosis fetalis in newborn

Patients with low circulating platelet counts or functionally abnormal platelets, to prevent or control bleeding.

  • Patients who are IgA deficient with documented presence of antibodies against IgA, for whom no IgA-deficient products are available.
  • Patients experiencing posttransfusion purpura (washing can help remove complement).
  • Patients with history of repeated severe allergic reactions to plasma-containing products.
  • von Willebrand factor antigen (vWF:Ag)
  • von Willebrand factor ristocetin cofactor (vWF:RCo) activity
  • FVIII activity

Learn more here.

Thrombotic thrombocytopenic purpura (TTP) and heparin-induced thrombocytopenia (HIT)

  • Unfractionated heparin > low molecular weight heparin (these differences are especially true at prophylactic doses)
  • IV heparin > SC heparin
  • Therapeutic or prophylactic dose heparin > heparin flush
  • Bovine>porcine heparin
  • von Willebrand factor (vWF) multimer assay
  • Ristocetin-induced platelet aggregation (RIPA)
  • vWF propeptide (vWFpp)
  • vWF factor VIII binding (vWF:FVIIIB)

Platelets collected using automated instrumentation (also called apheresis platelets).

  • Cyclooxygenase 1 (COX1) inhibitors such as aspirin
  • P2Y12 inhibitors such as:
    • Clopidogrel
    • Prasugrel
    • Ticagrelor
    • Cangrelor
  • Glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors such as:
    • Tirofiban
    • Eptifibatide
    • Abciximab
  • Thrombin receptor protease activated receptor inhibitor, vorapaxar

Systemic infection, solid and hematological malignancies, obstetric diseases (for example, abruptio placentae or amniotic embolism), trauma, aneurysms, and liver diseases.

From ISTH guideline on DIC

abciximab, eptifibatide, and tirofiban

Headache, facial flushing, tachycardia, and hyponatremia

Thrombotic type DIC and fibrinolytic type DIC.

Hereditary mutations in genes that encode thrombopoietin, the thrombopoietin receptor, or Jak2.

Meds, medications; MM, multiple myeloma; MDS, myelodysplastic syndrome; mets, metastases; DIC, disseminated intravascular coagulation.

Another perspective:

World Health Organization requires 4 major criteria or first three major criteria + 1 minor criterion.

Major:  

  • Sustained platelet count > 450 × 109/L
  • Bone marrow biopsy with characteristic changes
  • Not meeting WHO criteria for BCR-ABL+ CML, PV, PMF, myelodysplastic syndromes, or other myeloid neoplasm
  • Presence of JAK2CALR, or MPL mutation

Minor: presence of clonal marker or absence of evidence for secondary thrombocytosis

Learn more here.

ISTH/SSC Harmonization of the recommendations:

  • Fresh frozen plasma (FFP) recommended in patients with active bleeding or requiring an invasive procedure and either prolonged PT/aPTT (> 1.5 × normal) or decreased fibrinogen (< 1.5 g/L).
  • Cryoprecipitate recommended for patients with active bleeding plus severe hypofibrinogenemia (< 1.5 g/L) that persists despite FFP replacement.
  • Platelet transfusion recommended in patients with active bleeding plus platelet count < 50 × 109/L, or high risk of bleeding plus platelets < 20 × 109/L.

In patients with major bleeding (often in combination with corticosteroids) or in patients who require acute treatment and either cannot tolerate or do not respond to corticosteroids. Learn more here.

2011 ASH guideline, not addressed in the 2019 update
  • Cyclooxygenase 1 (COX1) inhibitors such as aspirin
  • P2Y12 inhibitors, including:
    • Clopidogrel
    • Prasugrel
    • Ticagrelor
    • Cangrelor
  • Glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors:
    • Tirofiban
    • Eptifibatide
    • Abciximab

Atypical HUS and infection-induced HUS, including Shiga toxin-producing Escherichia coli-associated (STEC) HUS and S. pneumoniae-associated HUS.

Systemic lupus erythematosus (SLE), infections (especially HIV and hepatitis C virus [HCV]), and lymphoproliferative disorders

Infection (with or without DIC) and medications (including heparin and non-heparin agents).

3 pillars of treatment are:

  • Treat underlying disease that triggered DIC.
  • Provide replacement therapy where appropriate.
  • Inhibit thrombin and fibrin formation where appropriate.

  • Type 1 – 75%
  • Type 2 – 20%
  • Type 3 – 5%
  • Type 2A – decreased secretion or increased cleavage of high-molecular-weight multimers.
  • Type 2B – increased vWF binding to platelet glycoprotein Ib (GPIb) alpha receptor with rapid clearance of platelet-vWF complex.
  • Type 2M – defective binding to platelet GPIb alpha receptor or collagen; M for multimer.
  • Type 2N – defective vWF binding to factor VIII; N for Normandy, where it was discovered.

Learn more here.

Increased platelet destruction, decreased platelet production and sequestration (hypersplenism).

A group of disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia and microthrombi leading to ischemic tissue injury. Laboratory tests reveal thrombocytopenia and hemolytic anemia with red blood cell fragmentation (schistocytes) on the peripheral blood smear.

TMA, thrombotic microangiopathy; TTP, thrombotic thrombocytopenic purpura; HUS, hemolytic uremic syndrome; STEC HUS, Shiga toxin-producing Escherichia coli HUS; aHUS, atypical HUS; HTN, hypertension; CTD, connective tissue disease.

About 25% lower than in persons with other blood types.

Aging, pregnancy, inflammation (vWF is an acute phase reactant)

  • With aging
  • In pregnancy
  • With stress (acute phase reactant)
  • In African Americans (vWF:Ag levels 20% higher compared to white patients, but vWF:RCo not affected)

 Discontinue non-heparin anticoagulant and resume heparin.

  • Continue heparin.
  • No need for alternative anticoagulant.
  • HIT antibody testing not recommended.
  • Discontinue heparin.
  • Initiate a non-heparin anticoagulant at therapeutic intensity.
  • Test for HIT antibodies.

Anti-PF4/heparin antibodies of all isotypes (IgG, IgA, IgM, or polyclonal or polyspecific assays) or IgG isotypes.

Thrombocytopenia with normal Hb and white cell count.

A disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13

Atypical hemolytic uremic syndrome

1-desamino-8-D-arginine vasopressin, also called desmopressin

Disseminated intravascular coagulation 

Drug-induced thrombocytopenia

Essential thrombocythemia

Heparin-induced thrombocytopenia

Heparin-induced thrombocytopenia with thrombosis

Immune thrombocytopenia

Myeloproliferative leukemia virus oncogene, also known as the thrombopoietin (TPO) receptor

Platelet factor 4

 Shiga-like toxin producing Escherichia coli (E. coli) hemolytic-uremic syndrome (STEC-HUS)

Thrombotic microagniopathy

Thrombopoietin 

Thrombotic thrombocytopenic purpura

von Willebrand disease

Von Willebrand factor

In one study:

  • Normal platelet count in 84.6%
  • Thrombocytosis (> 400 × 10 9/L) in 13.3%
  • Thrombocytopenia (< 150 × 10 9/L) in 2.1%

Based on a landmark randomized study in 1991 (see abstract below), plasma exchange was reported to be associated with a mortality rate of about 10%, vs. 90% in historical controls.

  • von Willebrand disease
  • Inherited platelet function disorders (IPFDs), including:
    • Bernard-Soulier syndrome
    • Glanzmann thrombasthenia
    • Montreal platelet syndrome
    • Scott syndrome
    • Dense granule storage pool disorders
    • Alpha granule storage pool disorders
    • MYH9-associated disorders
    • Paris-Trousseau/Jacobsen syndrome
    • Congenital amegakaryocytic thrombocytopenia
    • Congenital malformation syndromes

Read more here.

Platelet count > 1,000-1,500 × 109/L

Most platelets are 1.5-3 μm in diameter. Small platelets are less than 1.5 μm in diameter. Large platelets usually range from 4 to 7 μm. Giant platelets are larger than 7 μm and usually 10-20 μm in diameter. Platelets that are larger than the size of the average red cell in the field qualify as giant platelets. Seen in many different reactive, neoplastic, and inherited conditions including myeloproliferative and myelodysplastic disorders, autoimmune thrombocytopenia, in association with severe leukemoid reactions, May-Hegglin anomaly and Bernard-Soulier syndrome.

150-450 x 109/L

150-450 x 109/L

A platelet transfusion to prevent bleeding.

Alphanate is a high-purity factor VIII/von Willebrand factor (vWF) lyophilized concentrate used in patients with von Willebrand disease (vWD). it is FDA approved for adult and pediatric patients with vWD having surgery or invasive procedures in whom desmopressin (DDAVP) is ineffective or contraindicated.

Autosomal dominant disorder characterized by variable bleeding tendency, and variable association to hearing loss, cataracts, and nephritis. Encompasses Sebastian, May-Hegglin, Fechtner, and Epstein syndromes. Caused by mutation in MYH9 encoding nonmuscle myosin IIA. Learn more here.

Upshaw-Schulman syndrome

Immune TTP

A type of thrombotic microangiopathy characterized by uncontrolled complement activation, microangiopathic hemolytic anemia, thrombocytopenia, and organ dysfunction, especially renal failure. Learn more here.

A rare autosomal recessive disorder characterized by moderate to severe mucocutaneous bleeding, unusually large platelets, low platelet count (thrombocytopenia), and prolonged bleeding time (though this test is rarely performed). Caused by mutations in genes encoding proteins in the glycoprotein (GP) Ib/IX/V complex. Learn more here.

Autosomal recessive disorder characterized by moderate to severe bleeding, primarily mucocutaneous, from childhood. Characterized by mild thrombocytopenia with giant platelets, normal aggregation to all agonists except ristocetin and a prevalently severe bleeding phenotype. Learn more here.

A humanized anti-von Willebrand factor (vWF) single-variable-domain immunoglobulin (nanobody) that targets AI domain of vWF, preventing its interaction with platelet glycoprotein 1b-IX-V, FDA approved for treatment of adults with immune TTP in combination with plasma exchange and immunosuppressive therapy.

HIT that develops or worsens after heparin has been discontinued. Thrombotic manifestations are delayed for days to weeks after heparin discontinuation and discharge.

According to Warkentin, TE:

There is a disorder called “delayed-onset HIT”. Despite its name, the timing of delayed-onset HIT resembles that of “typical onset HIT”, i.e. the platelet count fall begins 5–10 days after the immunizing exposure to heparin. Thus, there really is not any “delay” in onset of HIT (the term “delayed-onset” was intended to help the clinician remember that HIT can began several days after all heparin has been stopped). In recent years, the concept of delayed-onset HIT has expanded to include patients whose HIT worsens even after stopping heparin… patients’ HIT antibodies activate platelets in the absence of heparin, with activation inhibited by high heparin (100 IU/ml) and by Fcγ receptor blocking antibodies. These patients have a higher frequency of HIT-associated DIC, lower platelet count nadirs, and greater likelihood of severe sequelae, including venous limb gangrene. Sometimes, heparin “flushes” are the only proximate heparin exposure identified.

Learn more here.

DDAVP is a synthetic derivative of antidiuretic hormone vasopressin that acts through type 2 vasopressin receptor.

Autosomal dominant disorder characterized by cleft palate, congenital cardiac abnormalities, developmental disabilities, facial dysmorphisms, immunodeficiency with parathyroid and thymus abnormalities, and mild to significant bleeding. Caused by microdeletion of chromosome 22q11.2 including the GP1BB gene (encodes glycoprotein 1b-beta [GPIbβ]). Learn more here.

Acquired clinicopathological syndrome characterized by systemic activation of coagulation that may cause organ-damaging thrombosis and/or hemorrhage due to consumption of coagulation factors and platelets. Defined by ISTH as “an acquired syndrome characterized by the intravascular activation of coagulation with a loss of localization arising from different causes; can originate from and cause damage to the microvasculature, which if sufficiently severe, can produce organ dysfunction”.

Eculizumab is a monoclonal C5 antibody that inhibits terminal complement complex formation used as first line therapy in atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH).

The complement system is a major innate immune defense mechanism. Complement may be activated by the classical, lectin or alternative pathways, all leading to the cleavage of the inactive central component C3 to biologically active C3b. C3b binds covalently to any surface, either foreign or self. When C3b is bound to positively charged surfaces (called alternative pathway activator surfaces as present in microorganisms) C3b interacts with factor B (FB) to form the C3 convertase (C3bBb) of the alternative pathway amplification loop and may generate a C5 convertase leading to the release of C5a, which is also an anaphylatoxin, and C5b which initiates the formation of the membrane attack complex (MAC), by binding C6 and C7. The C5b67 inserts into the membrane where it binds C8 and many molecules of C9, forming a pore. It can be cytolytic, forming a transmembrane channel, which causes osmotic lysis of the target cell or sublytic, associated with cell activation. In order to avoid complement hyperactivation, the alternative pathway C3 convertase is tightly regulated. Source

A vasomotor disturbance characterized by periodic attacks with triad of increased temperature, erythema, and burning pain resulting from hyperperfusion of skin areas, especially in the feet and hand. Typically relieved by cooling and aggravated by warming. May be primary or secondary. Causes of secondary erythromelalgia include polycythemia vera and essential thrombocythemia.

Learn more here.

Intermittent attacks with triad of increased temperature, erythema, and burning pain that primarily affects the feet and hands. A characteristic symptom of essential thrombocythemia. Learn more here.

Combined immune thrombocytopenia (ITP) and autoimmune hemolytic anemia. Learn more here.

A group of rare hereditary disorders associated with low platelet count and variable degree of bleeding complications. Learn more here.

Inborn error of metabolism leading to accumulation of glucocerebroside within lysosomes of cells.

Learn more here.

Autosomal recessive inherited platelet function disorder characterized by moderate to severe mucocutaneous bleeding. Caused by mutation in genes that encode for glycoproteins αIIbβ3 on platelet surface, leading to impaired platelet aggregation.

Most common autosomal recessive inherited platelet function disorder characterized by moderate to severe bleeding from childhood such as gastrointestinal bleeding, epistaxis, and gingival bleeding (heterozygotes are typically asymptomatic). Caused by mutations in genes that encode for glycoproteins αIIbβ3 on platelet surface, leading to impaired platelet aggregation. Learn more here.

Humate-P is pasteurized plasma-derived von Willebrand factor (vWF)/factor VIII lyophilized concentrate with high vWF activity and higher proportion of high-molecular-weight vWF multimers than other vWF/factor VIII concentrates. Humate-P is FDA approved for adults and children with von Willebrand disease (vWD).

The prothrombin time (PT)

Thrombotic thrombocytopenic purpura (TTP), named after the physician Eli Moschcowitz who first described the condition.

Subtle hemostatic dysfunction without obvious clinical symptoms. May progress to overt DIC.

Decompensated hemostasis with bleeding and thrombotic manifestations.

A rapid and reproducible test that measures primary platelet-related hemostasis using small amount of anticoagulated whole blood under conditions of high shear, with platelet plug formation. The assay is dependent on von Willebrand factor (vWF) and not fibrinogen.

Employs 3 cartridges, containing:

  • Collagen (2 μg equine type I) and epinephrine (10 μg)-coated membrane
  • Collagen (2 μg equine type I) and adenosine-diphosphate (50 μg)-coated membrane
  • Prostaglandin E1 (5 ng) and ADP (20 μg)-coated membrane

For each cartridge:

  • Whole blood (usually 800 μl) is placed into the sample reservoir, and the sample aspirated under a constant vacuum, passing with high shear force through a capillary and a microscopic aperture in the membrane.
  • This results in platelet activation, attachment, and aggregation, forming a stable platelet plug at the aperture.
  • The instruments report a ‘closure time’, which is the time required for full aperture occlusion and cessation of blood flow.

The instruments are very sensitive to von Willebrand factor defects/deficiencies, and therefore to VWD and to severe platelet function defects, including Bernard Soulier Syndrome or Glanzmann’s Thrombasthenia, but only moderately sensitive to mild platelet defect.

Both PFA-100 and PFA-200 systems employ similar mechanical processes, but the PFA-200 has more advanced software and a modern user interface including a touch screen.

Innnovance PFA-200 system

Learn more here.

Repeated failure to achieve adequate response to platelet transfusions

Genetic or acquired conditions associated with absent or reduced numbers of platelet granules or granules that are unable to empty their contents into the bloodstream. Learn more here.

Autosomal dominant condition caused by a mutation in the gene encoding platelet GPIb alpha receptor, which leads to increased binding of platelets to von Willebrand factor (vWF). Learn more here.

Autosomal dominant condition associated with mild to moderate mucocutaneous bleeding caused by gain-of-function mutation in the megakaryocyte/platelet-specific gene encoding GPIbα, leading to increased affinity to von Willebrand factor, removal of high-molecular-weight von Willebrand factor from the circulation, and thrombocytopenia. Often confused with type 2B-VWD, a disorder in which gain-of-function variants of VWF are responsible for increased GPIbα-vWF binding. Learn more here.

A rare, life-threatening syndrome caused by marked protein C deficiency and characterized by disseminated intravascular coagulation (DIC) and endovascular thrombosis resulting in characteristic pattern of cutaneous purpura. See image.

HIT associated with abrupt platelet count fall (within 24 hours); occurs in patients who already have circulating anti-PF4/heparin antibodies because of recent heparin exposure (within the past 100 days).

First-line therapy includes corticosteroids and/or IV immunoglobulin (IVIG [or anti-D immune globulin (anti-D)]. Patients who are not bleeding should be started on steroids (prednisone 1-2 mg/kg up to a maximum of 80 mg daily) or dexamethasone 40 mg PO or IV daily x 3 days. If there is a particularly high risk of bleeding, IVIG may be added to the regimen.

2019 ASH clinical guideline
  • Functional assay that measures the ability of ristocetin to promote platelet aggregation in the presence of vWF.
  • Ristocetin is an antibiotic found to agglutinate platelets due to binding of vWF and platelet glycoprotein Ib (GPIb).
  • Ristocetin binds to vWF, inducing a conformational change in vWF which increases its binding to platelets.

Rituximab is a monoclonal antibody that targets CD20 antigen present on B lymphocytes.

Autosomal dominant or recessive disorder characterized by moderate to severe bleeding including menorrhagia, hematoma, and epistaxis. Caused by mutations in TMEM16F (ANO6) gene encoding transmembrane protein 16F (calcium-activated chloride channel). Learn more here.

A rare variant of HIT that develops without prior heparin exposure.

Learn more here.

  • Thrombocytopenia that results from platelet clumping in vitro.
  • An in vitro artifact with no clinical consequence.
  • Usually caused by EDTA-dependent antibodies, but may also occur with poor specimen collection and/or handling.
This patient was a 67-year-old man with chronic kidney disease. Note the significant platelet clumping (arrows) on a blood smear from a sample obtained in EDTA-containing tube. Blood obtained this way yielded a falsely low platelet count ( pseudothrombocytopenia) which was corrected when blood was taken in a heparin-containing tube  (50x).

HIT in which platelets are recovered, but HIT antibodies are still positive.

A clinical prediction rule used to predict the likelihood (pretest probability) of HIT. Includes a consideration of magnitude of platelet count drop, timing of platelet count drop, presence of thrombosis and presence of alternative causes of the reduced platelet count. See calculator.

Parameter2 points1 point0 pointsComment
ThrombocytopeniaPlatelet count fall > 50% AND platelet nadir ≥ 20 × 109 L−1Platelet count fall 30%–50% OR platelet nadir 10–19 × 109 L−1Platelet count fall < 30% OR platelet nadir < 10 × 109 L−1Fall from highest platelet count that immediately precedes the putative HIT-related platelet count fall. 95% of cases of HIT are reported to develop in temporal association with heparin therapy; typically > 50% platelet count fall, but not to levels < 20 × 10 9 /L; only a few patients show 30%-50% platelet count fall; typical nadir is 40-80 × 109/L, with median of 55 × 109/L.
Timing of platelet count fall

Clear onset between days 5 and 10 OR platelet fall ≤ 1 day (prior heparin exposure within 30 days)Consistent with days 5–10 fall, but not clear (e.g. missing platelet counts) OR onset after day 10 OR fall ≤ 1 day (prior heparin exposure 30–100 days ago)Platelet count fall < 4 days without recent heparin exposureDay 5 to 10 for initial platelet count fall with day 0 representing first heparin exposure; earlier fall if patient exposed to heparin with previous 30 days. Days are rounded off. For example, day 4.3 would count as day 4.
Thrombosis or other sequelae

New thrombosis (confirmed) OR skin necrosis at heparin injection sites OR acute systemic reaction after intravenous heparin bolusProgressive or recurrent thrombosis or non-necrotizing (erythematous) skin lesions or suspected thrombosis (not proven.None
Other causes for thrombocytopeniaNone apparentPossibleDefinite

Scoring 0, 1, or 2 points for each of 4 categories, maximum possible score = 8 Low score (0-3 points), intermediate score (4 or 5 points), high score (6-8 points).

  • Low score 0-3 points
  • Intermediate score 4-5 points
  • High score 6-8 points

Low 4Ts score may rule out HIT but high 4Ts score may not be sufficient to diagnose HIT.

>10%

Autoantibodies to ADAMTS13

Caused by mutations in genes encoding proteins in the megakaryocyte/platelet-specific glycoprotein (GP) Ib/IX/V complex.

Caused by mutation in genes that encode for glycoproteins αIIbβ3 on the platelet surface, leading to impaired platelet aggregation. Learn more here.

Autoantibodies that recognize platelet factor 4 (PF4) bound to heparin; the resulting antibody-antigen complex activates platelets, resulting in mild to moderate thrombocytopenia and thrombosis. Learn more here.

Congenital or acquired deficiency of the von Willebrand factor (vWF) cleaving protein, ADAMTS13

Autosomal recessive disorder characterized by variable oculocutaneous albinism, progressive neurologic dysfunction, severe immunodeficiency, recurrent life-threatening infections , and mild bleeding. caused by mutations in the LYST gene encoding a protein involved in granule trafficking and fusion.

  • Thrombocytopenia
  • Microangiopathic hemolytic anemia (MAHA)
  • Neurological changes (often fluctuating)
  • Renal impairment
  • Fever

Defined by the Scientific and Standardization Committee (SSC) on DIC of the International Society on Thrombosis and Haemostasis (ISTH) as an acquired syndrome characterized by the intravascular activation of coagulation with a loss of localization arising from different causes; can originate from and cause damage to the microvasculature, which if sufficiently severe, can produce organ dysfunction.

Platelet count that is < the 2.5th percentile of normal platelet count range, with the traditional cutoff for the lower limit being 150 × 109/L.

Primary thrombocytosis is caused by a clonal disorder of hematopoietic stem cells or by inherited mutations (familial or congenital thrombocytosis). Secondary or reactive thrombocytosis occurs when signals (often cytokines like IL-11) promote proliferation and differentiation of normal megakaryocytes. Learn more here.

Mechanisms of thrombocytosis. Primary or clonal thrombocytosis involves autonomous growth of stem cells or megakaryocyte progenitor cells owing to mutations in genes involved in cell growth and differentiation/maturation. In these cases, the megakaryocyte progenitors are impervious to normal inhibitory signals and proliferate uncontrollably. In secondary (reactive) thrombocytosis, the megakaryocytes are perfectly normal. They are simply marching to the tune of the microenvironment, dividing and differentiating in response to extracellular signals such as thrombopoietin and interleukn-6. Finally, the spleen normally pools about one-third of the circulating mass of platelets. When it is removed, or it is hypofunctioning, the sponge effect of the spleen is lost and platelet counts may increase.

In primary TTP, there is no underlying predisposing condition. By contrast, secondary TTP is associated with another clinical diagnosis or underlying cause. In both cases, ADAMTS13 activity levels are, by definition, <10%.

TPO, thrombopoietin, TPO-R, thrombopoietin receptor; ET, essential thrombocythemia; MPN, myeloproliferative neoplasms; MDS, myelodysplasia.
  • Normal organ function → 2 μg/kg/min 
  • Liver dysfunction (bilirubin >1.5 mg/dL) → 0.5-1.2 μg/kg/min 
  • Heart failure, anasarca, postcardiac surgery → 0.5-1.2 μg/kg/min 

Learn more here.

Normal organ function → 0.15 mg/kg/h; renal or liver dysfunction → dose reduction may be appropriate.

375 mg/m2 IV weekly for 4 weeks.

  • HITT: 15 mg twice per day × 3 weeks, then 20 mg once per day 
  • Isolated HIT: 15 mg twice per day until platelet count recovery 

Learn more here.

Usually platelets > 30 x 109/L, though there are exceptions, e.g., in patients taking anticoagulants or anti-platelet agents, or in those undergoing a procedure.

Autosomal recessive disorder characterized by oculocutaneous albinism with nystagmus and visual acuity loss, immunodeficiency, mild bleeding pulmonary fibrosis, granulomatous colitis, and neutropenia, depending on the subtype. Caused by mutations in genes encoding proteins involved in vesicle formation and trafficking. Learn more here.

The International Society on Thrombosis and Haemostasis (ISTH) scoring system was developed by the Scientific and Standardization Committee on Disseminated Intravascular Coagulation and published in 2001. It is makes use of laboratory tests available in almost all hospital laboratories.

ParameterScoreComment
Fibrinogen (g/L)>1 (0)
<1 (1)
Overall sensitivity of low fibrinogen level reported to be about 30%
Prothrombin time (PT) (seconds)<3 (0)
3-6 (+1)
>6 (+2)
Elevated in 50%-60% of patients with DIC at some point during course of illness
Platelet count (109/L)>100 (0)
50-100 (+1)
<50 (+2)
Thrombocytopenia reported to occur in up to 98% of DIC cases
D-dimers or FDPsNo increase (0)
Moderate increase (+2)
Severe increase (+3
)
Elevated FDPs and D-dimers are sensitive, but not specific for DIC
Data are presented as values with number of points in parentheses. A total score of ≥5 is compatible with diagnosis of DIC

See ISTH calculator

Original publication on the ISTH score can be found here.

7-10 days

7-10 days

Represents mean volume of platelets; usually reported as femtoliters (fL), calculated by dividing plateletcrit by number of platelets (analogous to calculation of mean red blood cell volume [MCV]). Normal range is 8-12 fL. It is high in cases of thrombocytopenia caused by peripheral destruction. MPV is low in cases of thrombocytopenia caused by megakaryocyte hypoplasia.

MPV is measured by most modern automated hematology analyzers, but the value is not always included in the complete blood count.

IVIG reduces Fc receptor-mediated clearance of platelets by the reticuloendothelial system.

8-10 g/dL

50-70 x 109/L

10-30 × 109/L

Von Willebrand disease

von Willebrand disease – prevalence 0.1-1% of general population

Veins, especially lower-limb deep vein thrombosis (DVT) and pulmonary embolism (PE).

Plasma exchange

Receptor for murine myeloproliferative leukemia virus, subsequently discovered to be the receptor for thrombopoietin, the primary driver of platelet production.

MPL is the human homolog v-mpl, viral oncogene that is responsible for transforming myeloproliferative leukemia virus (MPLV)-infected hematopoietic progenitors. MPL has two isoforms (MPL-P and MPL-K) which differ at their 3′ ends due to alternative splicing, leading to distinct cytoplasmic domains. MPL-P is the dominant form, and is responsible for signal transduction. Source.

Learn more here.

Autosomal dominant disorder characterized by mild bleeding tendency, developmental delay, cardiac, skeletal, urogenital, central nervous system, gastrointestinal, and craniofacial abnormalities. Moderate to severe thrombocytopenia with giant alpha-granules in platelets that fail to release their contents upon stimulation with thrombin.

ADAMTS13 deficiency leads to reduced cleavage of ultra large vWF multimers, which leads to increased platelet aggregation and occlusion of small blood vessels.

A clinical prediction score that predicts severe ADAMTS13 deficiency in hospitalized patients with suspected thrombotic microangiopathy.

Plasmic score from MdCal

About 1 in 5,000 hospitalized patients develop HIT.

About 15%, typically those with concomitant disseminated intravascular coagulation (DIC).

Thrombocytopenia reported in 77%-85% of patients with cirrhosis.

7%-10% of pregnancies are associated with thrombocytopenia. 70-80% of these patients have “gestational” thrombocytopenia.

About 50%

15-50%

0.1% – 1% of the population.

IVIG can be administered either high dose (1 g/kg daily for 1–2 days) in emergent settings or lower dose (e.g., 0.4 g/kg daily for up to 5 days). Learn more here.

Plasma exchange (mainstay of treatment; ideally started within 4-8 hours of initial clinical diagnosis) and methylprednisolone (1 g/day IV for 3 days for adults) or high-dose oral prednisolone (for example, 1 mg/kg/day) and (in some cases) rituximab or caplacizumab; for secondary TTP, same treatment as with primary TTP in addition to treatment of the underlying disorder.

Guideline recommendations:

ISTH guidelines for treatment of thrombotic thrombocytopenic purpura:

The panel was unable to make a more detailed recommendation on a preferred dosage and type of corticosteroids (eg, prednisone, or methylprednisolone).
The data informing this recommendation are from nonrandomized trials.

British Committee for Standards in Haematology (BCSH) guidelines on diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies:

UFH is associated with an ∼10-fold greater risk of HIT than LMWH.

 5% to 10% daily risk of thromboembolism, amputation, and death

Serotonin release assay is a functional assay used to identify pathogenic IgG antibodies capable of binding and cross-linking platelet Fc gamma RIIA and triggering platelet activation. SRA assay is highly specific with positive predictive values of 90-100%. Used to confirm or rule out diagnosis of heparin-induced thrombocytopenia (HIT). Learn more here.

The SRA is a functional assay used to diagnose HIT. It identifies pathogenic IgG antibodies capable of binding and cross-linking platelet Fc gamma RIIA and triggering platelet activation. Test results are expressed as percentage of serotonin release compared to maximum release after detergent-induced platelet lysis (100%). Positive test is > 20% release at therapeutic heparin levels and < 20% release at supratherapeutic heparin levels. Specificity about 95%, but lower sensitivity reported compared with immunoassays. Read more here.

Serotonin release assay begins with normal donor platelets that are incubated with radioactive 12C-serotonin. The platelets, which now contain 12C-serotonin, are then incubated with control buffer or patient serum or plasma and various concentrations of heparin. HIT serum (or plasma) causes platelet activation at therapeutic (0.1–0.3 IU/ml) heparin concentrations, but not in the presence of high (100 IU/ml) heparin concentrations (not shown).

Eculizumab (plasma exchange within 24-48 hour of onset or admission if eculizumab is not immediately available). Eculizumab is a monoclonal C5 antibody that inhibits terminal complement complex formation.

40-80 × 109/L, with median of 55 × 109/L

5-10 days following first heparin exposure.

HIT is an iatrogenic disorder usually mediated by IgG antibodies that target multimolecular complexes of PF4 and heparin, leading to platelet activation, generation of procoagulant platelet-derived microparticles and activation of white blood cells and endothelial cells. The net result is a profoundly hypercoagulable state.

Congenital thrombotic thrombocytopenic purpura (TTP)

Blood. 1960;16:943-57.
N Engl J Med. 1978;298:1350-2

Learn more here.

X-linked recessive inheritance disorders characterized by eczema, microthrombocytopenia, immune deficiency, increased risk of developing lymphoma and autoimmunity, and clinically significant bleeding present from infancy. Wiskott Aldrich syndrome is caused by genetic changes in the WAS gene and is inherited in an X-linked manner. Wiskott-Aldrich syndrome, X-linked thrombocytopenia (XLT), and X-linked neutropenia (XLN) are known as ‘WAS-related disorders’ because these diseases are all caused by genetic changes in the WAS gene, and have overlapping symptoms ranging from severe to mild (Wiskott-Aldrich syndrome is the most severe).

A group of disorders characterized pathologically by occlusion of small (and occasionally large) blood vessels and clinically by thrombocytopenia, microangiopathic hemolytic anemia (MAHA) and end organ dysfunction. Learn more here.

A clinical syndrome that includes microangiopathic hemolytic anemia, thrombocytopenia, and organ damage caused by endothelial cell injury and thrombotic occlusion of small blood vessels. Learn more here.

A thrombotic microangiopathy (TMA) caused by deficiency of ADAMTS13, a von Willebrand factor cleaving protease, which leads to platelet-mediated occlusion of microvessels, thrombocytopenia, microangiopathic hemolytic anemia, and widespread multiorgan thrombosis and injury.

Type 1 vWD is the least severe form of the vWD. It is inherited in an autosomal manner and is associated with mild-to-moderate quantitative vWF deficiency (5-30 units/dL). Learn more here.

  • The most common type; accounts for about 60%-85% of cases.
  • The mildest form of disease.
  • Autosomal dominant inheritance.
  • Sequence variants absent in about 35% of patients.
  • Plasma vWF level < 30 units/dL, parallel reduction in factor VIII levels.
  • Bleeding in type 1 vWD is caused by a decrease in concentration of vWF, not a selective reduction in large multimers.
  • About 15% of cases (called type 1C) are associated with increased clearance of VWF.

Type 2 vWD involves a qualitative abnormality of the von Willebrand factor (vWF). There are 4 subtypes, each associated with a specific functional defect. See more here.

  • Accounts for about 20% of cases of vWD.
  • Subtypes include:
    • 2A
      • most common subtype 
      • deficiency of large (intermediate and high-molecular-weight) multimers 
      • impaired von Willebrand factor (vWF) binding to collagen and platelets
    • 2B
      • Gain-of-function mutation which causes increased vWF binding to platelet GPIb alpha with rapid clearance of platelet-vWF complex.
      • Results in deficiency of high-molecular-weight multimers and thrombocytopenia in 40% of affected patients.
      • Phenocopy of platelet type vWD.
    • 2M (M for multimer)
      • Loss-of-function mutation which decreases vWF binding to platelet GPIb alpha or collagen.
      • Normal vWF multimer distribution.
    • 2N (N for Normandy, the location where it was discovered)
      • Loss-of-function mutations in vWF that cause decreased vWF binding to factor VIII with abnormally increased clearance of factor VIII.
      • May mimic mild hemophilia A.
  • Autosomal dominant inheritance.
  • Most cases caused by missense mutations, which are usually limited to specific functional domains.
  • ratio of von Willebrand factor ristocetin cofactor activity to von Willebrand factor antigen (vWF:RCo to vWF:Ag) typically < 0.7, with exception of type 2N and collagen-binding variant of type 2M.

Type 3 vWD (autosomal inheritance) is the most severe form of vWD. It is associated with complete deficiency in vWF. Represents only 5% of all vWD. Learn more here.

A bleeding disorder caused by quantitative or qualitative defects in von Willebrand factor (vWF) activity, which increases the risk of bleeding. Most cases are congenital (mutation in the VWF gene), though acquired vWD occurs in rare cases. vWD is the most common inherited bleeding disorder.

A  multimeric plasma glycoprotein that mediates the adhesion of platelets to the subendothelial surface of blood vessels. Synthesized and released by endothelial cells and platelets, and circulates as large multimers of varying size.

Vonvendi is a recombinant von Willebrand factor, FDA approved for use in adults with von Willebrand disease (vWD) for on-demand treatment and control of bleeding episodes. Contains large and ultra-large vWF multimers but lacks factor VIII (FVIII) so that patients may have to be supplemented with FVIII product.

Wilate is a high-purity factor VIII/von Willebrand factor (vWF) concentrate FDA approved for adult and pediatric patients with von Willebrand disease (vWD) in whom desmopressin is ineffective or contraindicated for on-demand treatment and control of bleeding and perioperative management of bleeding.

Humate P, Alphanate, Wilfactin, Vonvendi

Platelet count < 10-20 × 109

Prophylaxis for meningococcal infection (Neisseria meningitides) with vaccination, and antibiotics if treatment with eculizumab cannot be delayed until vaccine response. Per manufacture’s instructions:

  • Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.
  • Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of eculizumab, unless the risks of delaying eculizumab therapy outweigh the risk of developing a meningococcal infection. 
  • If urgent eculizumab therapy is indicated in an unvaccinated patient, administer meningococcal vaccine(s) as soon as possible and provide patients with two weeks of antibacterial drug prophylaxis.

80% primary, 20% secondary

Genetic abnormalities found in about 50%-70% of patients with atypical HUS. Learn more here.

  • Fresh frozen plasma
  • Platelet transfusion
  • Cryoprecipitate
  • Fibrinogen concentrate

Stop the coumadin and reverse with vitamin K (at the same time stopping heparin and starting an alternative anticoagulant).

Stop the vitamin K antagonist, and reverse with vitamin K concomitant with initiation of a non-heparin anticoagulant.

Type 2B, as these patients are at risk for platelet aggregation and thrombocytopenia.

Cardiac troponin, BUN and creatine, urinalysis, electrocardiogram and CT brain if neurological symptoms.

Mucocutaneous bleeding, including ecchymosis, petechiae, purpura, menorrhagia, epistaxis, and bleeding from lesions in the mouth and gastrointestinal tract.

Mucocutaneous bleeding is most common, including:

  • Petechiae
  • Purpura
  • Ecchymoses
  • Oral cavity bleeding
  • Gastrointestinal bleeding
  • Epistaxis
  • Menorrhagia
  • Hematuria

Intracerebral bleeding is rare. Hemarthrosis or extensive soft tissue hematoma suggest defects in secondary hemostasis.

Gray platelet syndrome, FI1B-RT, MYH9-related disease, and GATA1-related disease

WAS, XLT and CYCS-related thrombocytopenia

Secondary (reactive) thrombocytosis accounts for ≥ 85% of cases.

The VWF gene is located on the long arm of chromosome 12 and comprises 52 exons that encode 2813 amino acids.

Endothelial cells and megakaryocytes/platelets.

Type 2B vWD (gain-of-function defect in VWF that causes enhanced VWF–platelet interactions via platelet GPIb).

  • In type 2B VWD, VWF-GPIb platelet binding is pathologically enhanced, resulting in abnormal complexes between platelets and large adhesive forms of VWF. These complexes, not seen in other subtypes of VWD, are thought to account for the thrombocytopenia and depletion of large VWF multimers observed in many, but not all, cases of type 2B VWD.
  • The degree of thrombocytopenia can vary and may be exacerbated at times of increased VWF production or secretion, such as during physical effort, inflammation, or pregnancy.
  • Thrombocytopenia is rarely so severe as to be thought to contribute to clinical bleeding.
  • Thrombocytopenia, while a distinctive feature of type 2B VWD, is not always present at baseline.

Learn more here.

Patients undergoing cardiac surgery

Robert S. Evans, first author on paper that first described the syndrome in 1951.

Erik Adolf von Willebrand was a Finnish internist who described the first case of vWD in 1926.

From Thrombosis Research (2007) 120, S1

A Finnish physician, Erik von Willebrand, who published a description of a new bleeding disorder that he observed in a family
living in the Aland Islands in the Baltic Sea in 1926.

Hemodilution and platelet consumption cause reduction in platelet count in early days post op (typically within 4 days of surgery), which leads to increased levels of thrombopoietin. The thrombopoietin response to acute thrombocytopenia takes 3 to 4 days to increase platelet production by bone marrow megakaryocytes, and results in a physiological “overshoot” in the platelet count. Postoperative platelet counts peak at two- to threefold the patient’s preoperative platelet count at approximately postoperative day 14, before gradually returning to the patient’s baseline value over the next 14 days. Learn more here.

Coagulation

Yes. Desmopressin/DDAVP (1-deamino-8-D-arginine vasopressin) is a synthetic analogue of hormone 8-arginine vasopressin, an antidiuretic hormone.

Yes, they are 20-25% lower in individuals with type O blood group. 14% of individuals with type O blood have vWF levels ≤ 50 units/dL. Learn more here.

No. In unconfirmed atypical HUS, serum/plasma complement factor levels may suggest diagnosis but they are unreliable as direct diagnostic tests.

Fragmented RBCs can be detected by certain automated hematology analyzers based on analysis of fraction of small red blood cells (RBCs) in the context of normal RBC volume indices (mean corpuscular volume and width). Their presences should prompt a peripheral blood smear review.

Figure: A specific area below the RBC area in the RET scattergram is used for identification of fragmented red blood cells. Due to the absence of nucleic acids in red blood cells the intensity of the measured side fluorescence signals (SFL) is extremely low. In addition, the high-angle forward scatter (FSC) is lower than that of intact red blood cells. Each cell is plotted in the RET scattergram based on its fluorescence intensity (SFL on x-axis) and its high-angle forward scatter (FSC on y-axis), which reflects characteristics of both cell size and cellular content. The triangle indicates the detection area for fragmented red blood cells (FRC). Source.

Yes, DVT may rarely occur in arms of the upper extremity, splanchnic veins and cerebral veins.

No, they should be avoided in pregnancy. Vitamin K antagonists are also contraindicated in pregnancy. Pregnant women requiring anticoagulation should receive low molecular weight heparin.

From 2018 ASH guideline

Yes, and in fact they are now recommended as an option in the latest American Society of Hematology (ASH) guideline, especially for those who are not at high risk of bleeding and who do not have extensive clot burden.

No, factor XIII deficiency cannot be detected by routine clotting tests such as PT, aPTT, or thrombin time. Rather, it is detected by ammonia release or amine incorporation assays.

There is an increasing trend towards using DOACs in this clinical context based on recent clinical trials. For example, it was shown that edoxaban (a DOAC used in Europe) may be as effective as low-molecular-weight heparin (LMWH) in reducing venous thromboembolism (VTE) recurrence/bleeding. The latest guidelines from ACCP and NCCN (see below) recommend administering oral factor Xa inhibitor (apixaban, edoxaban, or rivaroxaban) rather than LMWH during initiation and treatment phase of deep vein thrombosis (DVT). Because edoxaban and rivaroxaban reported to be associated with higher risk of gastrointestinal major bleeding compared to LMWH in patients with luminal gastrointestinal malignancy, apixaban or LWMH may be preferred in these patients. Learn more here.

Therapeutic anticoagulation for venous thromboembolism in patients with cancer (NCCN Version 2.2021)

At minimum, all critically ill non-bleeding patients with DIC should receive prophylactic anticoagulation for venous thromboembolism.

Regarding therapeutic doses of heparin, the 2013 ISTH harmonization guideline states:

Anticoagulant treatment may be a rational approach based on the notion that DIC is characterized by extensive activation of coagulation. Although experimental studies have shown that heparin can at least partly inhibit the activation of coagulation in DIC, there are no RCTs demonstrating that the use of heparin in patients with DIC results in an improvement in clinically relevant outcomes… therapeutic doses of heparin should be considered in cases of DIC where thrombosis predominates (low quality evidence). The use of low molecular weight heparin (LMWH) is preferred to the use of unfractionated heparin (UFH) in these cases (low quality evidence).

Yes

Patients with type 2B vWD may have thrombocytopenia. Learn more here.

No

In patients with synthetic liver dysfunction, the vitamin K cycle is impaired, so even large doses of vitamin K are not effective. Partial response may be seen in those patients who are vitamin K deficient, for example those receiving broad-spectrum antibiotics. Example of a negative study here.

Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI) (AISF/SIMI) recommends against the routine administration of vitamin K to increase the plasma levels of coagulation factors in patients with cirrhosis:

IIV and oral vitamin K result in similar INR reversal at 24-72 hours, but onset of action is more rapid with IV vitamin K (4-6 hours) compared with oral (18-24 hours).

All are equally efficacious in patients without cancer and with normal renal function.

No, because neither test accurately reflects the in vivo hemostatic balance. 2016 AASLD practice guideline: “INR is not a reliable indicator of coagulation status in cirrhosis”.

One daily dose is sufficient. Recommended s.c. adult dosing of enoxaparin (Lovenox): 1 mg/kg twice daily or 1.5 mg/kg/day. Learn more here.

Generally no, unless the patient has underlying kidney disease or is pregnant.

Because these patients have reduced levels of both procoagulants and anticoagulants, and the INR/PT and aPTT do not detect changes in anticoagulants.

About 6.5 adverse events per 10,000 units reported in Canada. Such reactions include allergic reactions, transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO). Learn more here.

15%-20% of patients presenting with acute lymphoblastic leukemia, > 90% of patients presenting with acute promyelocytic leukemia.

Distal DVT 20%, proximal DVT 80%

Lower rates of pulmonary embolism, DVT recurrence and postthrombotic syndrome.

Comparable protection against venous thromboembolism (VTE) recurrence, less overall risk of bleeding (especially intracranial bleeding). Studies have shown that gastrointestinal bleeding may be increased in patients taking DOAC but these studies involve cohorts with atrial fibrillation, not VTE.

Discontinue warfarin and start dabigatran or apixaban when INR <2.0

Learn more here.

Discontinue warfarin and start rivaroxaban when INR <3.0.

Learn more here.

DDAVP 0.3 mcg/kg IV in 30-50 mL normal saline over 30 minutes. May be repeated 12-24 hours after first dose, depending on how well the patient responds, but no more than 2-3 doses should be given in order to avoid tachyphylaxis.

  • No FDA-approved reversal agents for fondaparinux; no specific antidote available.
  • Fondaparinux does not bind to protamine sulfate; therefore protamine sulfate is not recommended.
  • Consider activated PCC (aPCC) 20 units/kg.
  • If aPCC is contraindicated or not available, consider rFVIIa 90 mcg/kg.

For IV heparin:

  • Protamine sulfate dosing is 1 mg per 100 units of heparin, if heparin was given in the previous 2-3 hours.
  • Protamine sulfate is given slower than 5 mg/minute to minimize the risk of adverse reactions.
  • Maximum dose of protamine sulfate is 50 mg.

For SC heparin:

  • When heparin has been given subcutaneously (and therefore is cleared with a longer half-life) prolonged or repeated administration of protamine sulfate may be required.

See protamine reversal calculator.

  • Dabigatran:
    • Overlap warfarin with dabigatran for 3 days (normal renal function); 2 days (CrCl 30 to 50 mL/min); or 1 day (CrCl 15 to 30 mL/min); note that dabigatran can contribute to INR elevation or,
    • Overlap warfarin with dabigatran until the INR is therapeutic on warfarin.
  • Apixaban:
    • If continuous anticoagulation is needed, discontinue apixaban and start a parenteral anticoagulant with warfarin; continue the parenteral agent until the INR is therapeutic on warfarin. Note that apixaban can contribute to INR elevation or,
    • Overlap warfarin with apixaban until the INR is therapeutic on warfarin, testing right before the next apixaban dose to minimize the effect of apixaban on INR elevation.
  • Rivaroxaban:
    • Discontinue rivaroxaban and start a parenteral anticoagulant with warfarin; continue the parenteral agent until the INR is therapeutic on warfarin. Note that rivaroxaban can contribute to INR elevation or,
    • Overlap warfarin with rivaroxaban until the INR is therapeutic on warfarin, testing right before the next rivaroxaban dose to minimize the effect of rivaroxaban on INR elevation.

Start the second DOAC when the next dose of the first DOAC would have been due. Do not overlap.

Protamine sulfate 1 mg per 100 anti-Xa units if LMWH administered within last 9 hours. If ineffective, may give additional protamine sulfate 0.5 mg per 100 anti-Xa units.

The VKAs produce their anticoagulant effect by interfering with the cyclic interconversion of vitamin K and its 2,3 epoxide (vitamin K epoxide), thereby modulating the gamma-carboxylation of glutamate residues (Gla) on the N-terminal regions of vitamin K-dependent proteins, which include factors II, VII, IX, and X. The vitamin K-dependent coagulation factors require gamma-carboxylation for their procoagulant activity. Carboxylation is required for a calcium-dependent conformational change in coagulation proteins that promotes binding to cofactors on phospholipid surfaces. In addition, the VKAs inhibit carboxylation of the regulatory anticoagulant proteins C, S, and Z and thereby have the potential to be procoagulant.

Read more here.

The enzyme that modifies the vitamin K-dependent proteins such as factors II, VII, IX and X, is the vitamin K-dependent carboxylase (or vitamin K-dependent gamma glutamyl carboxylase [GGCX]). This enzymes results in the carboxylation of of Glu to Gla residues. Concomitant with this modification, a reduced vitamin K molecule is converted to vitamin K epoxide. Before it can be reused, this vitamin K epoxide must be converted back to reduced vitamin K by the vitamin K epoxide reductase (VKOR). It is not known whether the conversion of vitamin K to reduced vitamin K is accomplished by VKOR or a separate enzyme. Thus, the unidentified reductase is referred to simply as vitamin K reductase (VKR) or vitamin K quinone reductase. Warfarin inhibits vitamin K epoxide reductase complex subunit 1 (VKORC1), thereby dampening the carboxylation and the procoagulant potential of vitamin K–dependent coagulation factor. To the extent that VKOR contributes to the conversion of vitamin K to reduced vitamin K, warfarin inhibits both reduction steps (indicated by red line).

1 unit vWF:RCo/kg infused will result in recovery of 1.5-2 units vWF:RCo/dL in adults; 50 units vWF:RCo/kg will give a recovery of 75-100 units vWF:RCo/dL.

DDAVP increases the release of vWF and factor VIII from endothelial cell stores by releasing vWF from cytoplasmic organelles called Weibel-Palade bodies.

LMWH is derived from full-length, highly sulfated polysaccharide (unfractionated heparin) harvested from porcine mucosal tissue by chemical or enzymatic depolymerization, resulting in smaller size polysaccharide fragments (6-22 sugar residues). Heparin binds to antithrombin through a pentasaccharide region leading to the inhibition of thrombin and Factor Xa (FXa). . Only one third of heparin polysaccharide chains display anticoagulant properties implying that a specific sequence in the polysaccharide chain is required for this activity. The number of polysaccharide fragments determines which serine proteases are inactivated by antithrombin. Inactivation of thrombin requires that the heparin be long enough (> 18 sugar residues) to bind both antithrombin and thrombin, serving as a bridge between the protease and its inhibitor. By contrast, inactivation of FXa simply requires the pentasaccharide sequence to bind to antithrombin (there is no need for bridging FXa with antithrombin). The majority of LMWH is shorter than this threshold. Thus, most of its activity is exerted through factor Xa inhibition.

Inactivation of factor Xa and thrombin (IIa) by heparin. Heparin binds to antithrombin through a high affinity pentasaccharide sequence (noted by colored shapes). Antithrombin conformational structure is changed by binding to heparin, accelerating its interaction with thrombin or factor Xa. (Top) Unfractionated heparin (UFH) can inactivate both thrombin and factor Xa. High-molecular-weight heparin (> 18 sugar residues) is required to bind to thrombin, and binding to thrombin is required for its inactivation. (Bottom) Low molecular weight heparin (LMWH) catalyzes the inactivation of factor Xa by antithrombin. Because the majority of polysaccharide fragments in LMWH contain < 18 saccharide units, LMWH has less inhibitory activity against thrombin than UFH. Based on Kumano et al.

Related FAQs:

Vitamin K antagonists disrupt the carboxylation of vitamin K-dependent coagulation factors (factors II, VII, IX, and X; and protein C and protein S). Administration of vitamin K restores hepatic carboxylation of the vitamin K-dependent coagulation factors in a dose-dependent manner. Since this requires new protein synthesis, administration of vitamin K does not result in immediate correction of coagulopathy. 12-24 hours are required for a sufficient amount of newly synthesized carboxylated vitamin K-dependent coagulation factors to reconstitute hemostasis.

The enzyme that modifies the vitamin K-dependent proteins such as factors II, VII, IX and X, is the vitamin K-dependent carboxylase (or vitamin K-dependent gamma glutamyl carboxylase [GGCX]). This enzymes results in the carboxylation of of Glu to Gla residues. Concomitant with this modification, a reduced vitamin K molecule is converted to vitamin K epoxide. Before it can be reused, this vitamin K epoxide must be converted back to reduced vitamin K by the vitamin K epoxide reductase (VKOR). It is not known whether the conversion of vitamin K to reduced vitamin K is accomplished by VKOR or a separate enzyme. Thus, the unidentified reductase is referred to simply as vitamin K reductase (VKR) or vitamin K quinone reductase. Warfarin inhibits vitamin K epoxide reductase complex subunit 1 (VKORC1), thereby dampening the carboxylation and the procoagulant potential of vitamin K–dependent coagulation factor. To the extent that VKOR contributes to the conversion of vitamin K to reduced vitamin K, warfarin inhibits both reduction steps (indicated by red line).

Learn more here.

Related FAQs:

Thrombosis occurs in one-third to one-half of patients with HIT. It may occur in veins, arteries or microvessels.

About 25% of all VTE events reported to be due to recurrent VTE.

aPTT; adjust to 1.5-3.0 times baseline.

aPTT; adjust to 1.5-2.5 times baseline.

A condition in which the blood’s ability to clot is impaired. .

DDAVP may be administered IV, subcutaneously, or by nasal spray.

No one laboratory test is specific for DIC. Clinical practice guidelines recommend using a clinical scoring system, such as the ISTH scoring system, which includes consideration of the platelet count, D-dimers, fibrinogen and the prothrombin time.

Subcutaneously, once daily. Learn more here.

≥ 35,000 units/day of unfractionated heparin needed to achieve therapeutic aPTT. Learn more here.

Based on clinical presentation (thrombocytopenia and/or thrombosis in temporal association with heparin therapy without other obvious causes) plus presence of platelet-activating antiplatelet factor 4 (PF4)/heparin antibodies. Clinical prediction scores, especially the 4T score, are helpful in estimating the pretest probability of HIT and determining whether heparin should be discontinued and if further testing for antibodies should be carried out.

Based on clinical presentation (thrombocytopenia and/or thrombosis in temporal association with heparin therapy without other obvious causes) plus presence of platelet-activating antiplatelet factor 4 (PF4)/heparin antibodies.

LWMH is monitored using a chromogenic heparin anti-Xa assay, which measures the ability of heparin to inhibit the activity of a known amount of activated factor X (FXa) in the reagent. The reagent includes an excess of antithrombin so that heparin in the sample is rate-limiting reagent for Xa inhibition. Heparin in the patient sample inhibits the enzymatic conversion of a Xa-specific chromogenic substrate to colored product by factor Xa (residual Xa is assayed using a chromogenic substrate specific for Factor Xa). Standard curves are created using multiple concentrations of UFH and LMWH and are used to calculate concentration in the patient plasma. Samples are obtained 4 hours following subcutaneous injection of LMWH. Therapeutic levels for enoxaparin (Lovenox) are typically 0.60-1.00 IU/mL for twice daily dosing.

  • Dose calculated based on the dose of heparin administered and the elapsed time since the last heparin dose.
  • 1 mg protamine sulfate IV neutralizes about 100 units of unfractionated heparin (UFH) given in past 2-3 hours (for example, protamine sulfate 25-35 mg would be administered in a patient receiving 1,000-1,250 units/hour UFH).
  • Given slowly over 10 minutes at a rate not to exceed 5 mg/minute.
  • Dose should not exceed 50 mg. When given at high dose, protamine sulfate can cause severe hypotension, cardiovascular collapse, noncardiogenic pulmonary edema, catastrophic pulmonary vasoconstriction, and pulmonary hypertension

Related FAQs:

  • One-third of the drug is eliminated in an unchanged form through the kidney.
  • Two-thirds metabolized by the liver and eliminated (about equally) through the kidney and gut.

  • Mild, factor VIII activity > 5%-40%
  • Moderate, factor VIII activity 1%-5%
  • Severe, factor VIII activity < 1%
Blood is drawn from a patient into a tube containing anticoagulant (citrate).
The sample is spun in a centrifuge to separate plasma from red cells and platelets.
Following centrifugation, plasma is on the top, red cells on the bottom.